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Summary 
In the pharmaceutical industry, the main goal of early phase in vivo studies is to 
assess pharmacokinetic properties of a compound in laboratory animals. These data 
provide a basis for selecting and optimizing drug candidates. However, formulation 
scientists face considerable challenges in finding intravenous preparations for first 
animal experiments. A common problem is the solubilization of lipophilic and 
sparingly water-soluble compounds. The search for suitable delivery vehicles often 
takes place under little compound availability, incomplete physicochemical property 
characterization, and time constraints. In addition, many experiments have recently 
generated distinct evidence about the impact of formulation vehicles on the drug 
pharmacokinetics by affecting transporters, metabolic enzymes, and distribution 
processes. Consequently, drug-excipient interactions are important to consider in the 
development of parenteral formulations intended for the proper evaluation of animal 
pharmacokinetics in vivo. Gaining a better understanding of potential interactions 
between drug and formulation in preclinical settings may play a crucial role in clinical 
and commercial phases of development as well. 
So far, little is known about drug-excipient interactions occurring in blood, especially 
following iv administration of low dosed compounds (<50 ng/mL in blood) including 
e.g. highly active drug substances, biomarkers, PET ligands, and microdoses. 
The purpose of the current work was to examine the potential of excipients 
commonly used in formulations to modify the blood distribution and protein binding of 
low dosed compounds under in vitro and in vivo conditions. Drug candidates in 
development at Novartis were used as model compounds and chosen based on 
different physicochemical and pharmacokinetic properties such as aqueous solubility 
(poor: COM1/COM2; good: COM3), lipophilicity (low: COM4; high: COM2), 
membrane permeability (low: COM5; high: COM3), and blood cell/plasma distribution 
(mainly in cells: COM3; mainly in plasma: COM4). Selected excipients comprised one 
cosolvent (polyethylene glycol 200, PEG 200), one complexing agent (hydroxypropyl-
β-cyclodextrin, HP-β-CyD), and three non-ionic surfactants (Cremophor EL, CEL; 
Solutol HS 15, Solutol; D-α-tocopheryl polyethylene glycol 1000 succinate, TPGS), 
most of them present in commercially available intravenous formulations. TPGS, 
which is used orally but not as an intravenous excipient, was chosen due to its 
chemical structure and intrinsic properties, particularly its benzyl ring and potential 
modulation of transporter/enzyme activities. 
Preliminary tests in vitro showed that selected excipients except for TPGS were 
non-hemolytic at 0.5% which is consistent with data reported in the literature. TPGS 
at 0.5% induced marked hemolysis after longer contact time (> 1h) in various species 
(mouse, rat, dog, and human), whereas TPGS at 0.1% showed no hemolysis under 
same conditions. Nevertheless, TPGS (0.5%) was used in the non-hemolytic time 
range for further investigations. The concentration of all excipients was set at 0.5% in 
test systems which is within the relevant range following intravenous dosing in 
animals. 
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In vitro, CEL, HP-β-CyD, Solutol, and TPGS influenced clearly the plasma protein 
binding and the distribution between blood cells and plasma of model compounds in 
mice (COM2) or rats (COM1, COM3, COM4, COM5). The addition of TPGS to 
incubations increased the distributed fraction of COM1 and COM2 in plasma with a 
concomitant decrease of drug unbound in plasma. Formulating COM4 in CEL and 
COM5 in Solutol lowered the protein binding, and the higher drug fraction unbound in 
plasma was associated with enhanced partitioning into blood cells. The presence of 
HP-β-CyD reduced both the uptake of COM3 into blood cells and the binding to 
plasma proteins. 
To assess the correlation between the in vitro findings and the in vivo situation, 
pharmacokinetics and tissue distribution were determined up to 1 h (within PET scan 
times) after an intravenous bolus injection of model compounds in formulations 
based on excipients or none (control) to animals, using in each case the excipient 
with the most pronounced interactions detected in vitro. Injection preparations 
contained the excipient to yield estimated blood concentrations of about 0.5%, similar 
to those used in the in vitro experiments. COM2 formulated in TPGS caused a higher 
accumulation of parent drug and metabolites in plasma without affecting tissue levels 
in mice. Administering COM3 in HP-β-CyD altered the disposition of COM3 
characterized by a lower binding to plasma proteins, decreased drug levels in the 
systemic circulation and skin, and a higher amount of unchanged drug in the urine. 
COM4 formulated in CEL resulted in a higher drug fraction unbound in plasma which 
had no impact on the pharmacokinetics and tissue distribution. The use of Solutol for 
COM5 application in rats was associated with decreased protein binding, longer 
persistence in the circulation, and higher concentrations in muscle and skin. Although 
TPGS induced a slight shift in the pharmacokinetic parameters of COM1 in rats, the 
compound turned out to be an inappropriate model compound due to its very rapid 
metabolism and elimination under in vivo conditions. 
These in vitro and in vivo findings demonstrated that commonly used excipients 
have a substantial potential for drug-excipient interactions in blood by altering protein 
binding and blood cell/plasma distribution which can influence the tissue distribution 
and elimination within the first hour after dosing. As a result, the formulation vehicle 
can be an important determinant for the disposition of low dosed compounds 
administered intravenously in animals. Moreover, results indicate a direct correlation 
of the excipient effect under in vitro and in vivo conditions. Therefore, blood 
distribution and plasma protein binding data generated in vitro seem to be 
appropriate to reveal potential drug-excipient interactions, thereby providing helpful 
information to improve the rational approach and strategy in the development of 
parenteral formulations at the preclinical stage. A better insight into the contribution 
of excipients to drug pharmacokinetics suggests also new possibilities of targeting 
different blood compartments and tissues by selecting the appropriate excipient. 
Such investigations should be considered to develop formulations suitable for 
intravenous administration of PET ligands where sub-therapeutic doses and short 
scanning times are used. 
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Abbreviations 
AGP α1-acid glycoprotein 
AUC Area under the drug concentration-time curve  
BCPR Ratio of concentration in blood cells to that in plasma, no units 
BPR Ratio of concentration in blood to that in plasma, no units 
C0 Initial plasma concentration at time zero 
CB Concentration of drug in blood 
CBC Concentration of drug in blood cells 
CEL Cremophor EL 
CP Concentration of drug in plasma 
EtOH Ethanol 
FP Drug fraction distributed in plasma, % 
fu Fraction of unbound to total drug concentrations in plasma, % 
funchanged AUC ratio of parent drug to that of total radioactivity, % 
Glu 5% aqueous solution of glucose 
H Hematocrit 
HDL High density lipoprotein 
HP-β-CyD Hydroxypropyl-β-cyclodextrin 
im Intramuscular 
iv Intravenous 
k Rate constant, h-1 
KP Distribution ratio of drug between tissue and blood/plasma, no units 
LC-RID Liquid chromatography-reverse isotope dilution 
LDL Low density lipoprotein 
LOQ Level of quantification 
LSC Liquid scintillation counting 
nd Not determined 
PEG 200 Polyethylene glycol 200 
PET Positron emission tomography 
SD Standard deviation 
Solutol Solutol HS 15 
TPGS D-α-tocopheryl polyethylene glycol 1000 succinate 
t1/2 Half-life, h 
V0 Volume of distribution based on initial drug concentration in plasma, L  
VLDL Very low density lipoprotein 
ρ Ratio of concentration in blood cells to that unbound in plasma, no units 
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1 Introduction 
1.1 The physiology of blood 
Blood is composed of cellular elements suspended in the plasma, an aqueous fluid 
in which solids are dissolved. Table 1-1 summarizes the main blood constitution of 
different laboratory animal species and humans. The normal range can vary, 
depending mainly on genetic and environmental factors and methods handling. 
Table 1-1 Normative data for laboratory animals and humans 
        Mouse (1,2) Rat (1,3,4) Human (5) 
Sex     Male Male Male 
Strain   OF1 Wistar  
Body weight (kg)  0.030 0.250 70 
Whole blood (ml/100 g)  7.2 (6.3-8.0) 7.2 ± 0.2 7.1 ± 0.6 
Plasma (ml/100 g)  3.2 3.9 ± 0.1 4.4 ± 0.5 
 
Total plasma proteins (g/100 
mL) 5.4 ± 0.2 5.7 ± 0.5 7.5 ± 0.4 
 Albumin (% plasma proteins) 61 ± 1 48 ± 3 62 ± 3 
 α1 globulin (% plasma proteins) 17 ± 2 4 ± 1 
 α2 globulin (% plasma proteins) 
12 ± 1                                 
(α globulin) 10 ± 2 9 ± 1 
 β1 globulin (% plasma proteins) 
 β2 globulin (% plasma proteins) 
20 ± 1                           
(β globulin) 
19 ± 1                         
(β globulin) 
11 ± 2                                        
(β globulin) 
 γ globulin (% plasma proteins) 7 ± 1 6 ± 1 15 ± 2 
Blood cells       
 Hematocrit (%)  43 ± 3 46 ± 2 44 ± 2 
 Red blood cells (x106 cells/µL)  9 ± 1 7 ± 1 5 ± 1 
 White cells (x103 cells/µL)  4 ± 2 6 ± 2 7 ± 1 
  Platelets (x106 cells/µL)   1.3 ± 0.4 1.2 ± 0.2 0.3 ± 0.1 
1.1.1 The blood cells 
The different specialized cells found in blood are white blood cells (leukocytes), red 
blood cells (erythrocytes) and platelets (thrombocytes). Of these, the erythrocytes are 
the most numerous and compose about one-half of the circulating blood volume. By 
carrying hemoglobin in the circulation, the red blood cells supply O2 to tissues and 
remove CO2. Leukocytes are classified as granulocytes (further classification in 
neutrophils, eosinophils, and basophils), lymphocytes, and monocytes. Acting 
together, these cells provide the body with a powerful defense against tumors, viral, 
bacterial, and parasitic infections. Compared to the other blood cells, the platelets are 
much smaller and aid in hemostasis by their primary function in blood clotting. 
Furthermore, blood cells can play a key role in binding and transporting of drugs in 
the circulation, thereby contributing to their pharmacokinetic and pharmacological 
characteristics (6,7). 
1.1.2 Plasma 
The plasma, the liquid portion of the blood, is a complex fluid composed of water 
(approximately 90%) and a large number of ions, inorganic molecules, and organic 
molecules in solution. These dissolved substances, primarily proteins, are in transit to 
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various parts of the body or aid in the transport of other substances. The plasma 
proteins consist of albumin, globulin, and fibrinogen fractions, which can be 
separated by electrophoresis. Electrophoretic separation followed by 
immunoprecipitation (immunoelectrophoresis) results in a further division of the 
proteins. If whole blood is allowed to clot and the clot is removed, the remaining fluid 
is called serum and has essentially the same composition as plasma except for the 
removed fibrinogen and few clotting factors (II, V, and VIII). Table 1-2 lists the main 
protein fractions with their main characteristics. The table also indicates that a large 
number of drugs associate with proteins within the bloodstream. Albumin is the major 
drug-binding plasma protein (8) followed by alpha 1-acid glycoprotein as the next 
important one (9). In recent years, studies have shown, that lipoproteins are also 
substantially involved in the binding/transport of drugs in the blood compartment (10). 
So far, γ-globulins play only a marginal role in plasma binding of drugs. 
Table 1-2 Proteins in human plasma 
Physiological Function
Albumin Prealbumin
Albumin
α1 globulin α1-acid glycoprotein Uncertain (acute phase protein)
α1-lipoprotein ("high Transporter Lipids
density lipoproteins")
α2 globulin Ceruloplasmin Transporter Copper
α2-Macroglobulin Enzyme inhibitor Serum endoproteases
α2-Haptoglobin Binding and carrier protein Cell-free hemoglobin
β globulin Transferrin Transporter Iron
β-lipoprotein ("low Transporter
density lipoproteins")
Fibrinogen Precursor to fibrin in hemostasis
γ globulin IgG, IgA, IgM, IgE Antigen Few basic compounds
Electro-
phoresis
Immuno-
electrophoresis
Protein fraction Binding characteristics
Drugs Endogenous entities
Lipoproteins: mainly lipophilic 
neutral and basic compounds
Humoral immunity 
(antibodies/immunoglobulins)
Lipids (mainly 
cholesterol)
Binding and carrier protein,                             
osmotic regulator
Hormones, amino 
acids, steroids, 
vitamins, fatty acids
Mainly basic and neutral 
compounds
Mainly acidic, but also basic 
and neutral compounds 
Lipoproteins: mainly lipophilic 
neutral and basic compounds
 
1.2 In vitro methods to investigate blood binding parameters 
The investigation of the partitioning of a drug in the blood compartment is essential 
in predicting its pharmacokinetic/-dynamic profile. In general, the unbound 
concentration of a drug in blood reflects more accurately pharmacological effects of 
the drug than its total concentration in blood (bound + unbound), because only the 
drug unbound to blood components is able to diffuse through the membranes and 
then reach the target organ (11). Furthermore, the binding to plasma proteins also 
relates to the volume of distribution and the clearance of the drug. For instance, 
many experimental and clinical studies have generated substantial evidence 
summarized by Akhlaghi (12), that the unbound fraction of cyclosporin in plasma 
correlates more closely with pharmacodynamic and pharmacokinetic characteristics 
of cyclosporin than its total blood concentration. Therefore, determination of extent 
and rate of blood/plasma distribution and plasma protein binding of a drug is 
important in both the discovery and clinical phases of drug development. 
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1.2.1 Blood distribution method 
The rate and extent of blood/plasma distribution of drugs is determined in vitro in 
spiked whole blood. The experiments are performed under controlled physiological 
conditions (pH 7.4, 37°C, gently shaken) to reflect the in vivo situation over the entire 
clinically relevant concentration range of the drug. Time samples are taken and 
centrifuged. Subsequently, drug concentrations in blood and plasma are determined 
to calculate the time required to reach equilibrium. The extent of blood/plasma and 
blood cell/plasma distribution derives from measured concentrations in blood and 
plasma and can be expressed with distribution parameters like FP, BPR, and BCPR. 
BPR
 
depends on the hematocrit of the whole blood used in the determination, 
whereas BCPR is independent of the hematocrit value. 
1.2.2 Protein binding methods 
Various methods are available for the determination of free drug concentration and 
protein-drug binding fraction in plasma (13,14,15), including conventional separation 
methods summarized in Table 1-3. However, the routinely used methods like 
ultrafiltration or equilibrium dialysis are limited in the case of lipophilic drugs due to 
their nonspecific adsorption to ultrafiltration device or to the dialysis membrane. 
Along with a trend to more lipophilic compounds observed in the pharmaceutical 
industry in recent years (16), these adsorption problems are expected to increase. As 
a result, ongoing method modifications and new methods are needed to overcome 
these difficulties. Overall, the selection of the method of binding assay depends upon 
the aim of the study and the physicochemical properties of the particular test 
compound including its formulation. 
The ratio of bound and total drug concentrations in plasma expresses the degree of 
drug binding to plasma proteins and ranges between values of 0 and 1. Based on 
these values, drugs can be classified into very highly bound (>0.95), highly bound 
(>0.90), poorly bound (<0.9), and little/not bound (<0.2). 
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Table 1-3 Conventional methods for determination of plasma protein binding 
Method Principle Advantages Disadvantages
Ultrafiltration
Ultracentrifugation
Gel filtration Adoptable for lipophilic 
drugs, automatable, 
binding differences 
detectable (e.g. 
affinity)
Complex handling, time 
consuming
Time consuming, expensive 
equipment, false estimation 
of free fraction by physical 
phenomena (e.g. 
sedimentation, back 
diffusion), protein 
contamination of free drug 
layer
Separation by size 
exclusion and affinity of 
column 
Separation by 
centrifugation at high 
speed in absence of a 
membrane 
No membrane effects, 
"natural environment", 
no dilution problems, 
adoptable for lipophilic 
and high MW drugs, 
evaluation of 
lipoprotein binding
Equilibrium dialysis 
(reference method)
Sample dilution, volume 
shifts, Donnan effects, 
nonspecific adsorption, 
sieve effect, time 
consuming, unsuitable for 
unstable drugs
Separation by filtration 
through a semipermeable 
membrane with defined 
molecular weight cutoffs 
accelerated by 
centrifugation or positive 
pressure (N2 gas, syringe) 
Equilibrium establishment 
between two 
compartments separated 
by semipermeable 
membrane with defined 
molecular weight cutoffs
Physiological 
conditions, universal 
binding method
Simply applicable, 
short analysis time, 
simple commercially 
available kits, no 
volume shifts, no 
dilution effects
Donnan effects, nonspecific 
adsorption, binding 
equilibrium changes during 
separation process, small 
amount for analysis, sieve 
effect
 
1.3 Characterization of drug candidates 
Successful candidates in drug development must have proper physicochemical 
properties in addition to acceptable pharmacokinetics, efficacy, and safety profiles. 
As a result, a clear understanding of compound characteristics and their correlations 
are helpful to rank and sort out unsuitable compounds in drug research (17,18). 
1.3.1 Physicochemical properties 
The chemical structure of a drug candidate is used in both predicting the 
pharmacology and selecting formulation strategies. Table 1-4 shows physico-
chemical parameters, which are critical for in vivo drug action. 
The molecular weight (MW) indicates roughly the size of a chemical entity and is 
connected to its membrane permeability, namely to the intestinal and brain 
penetration (16,19). 
LogP, the octanol-water partition coefficient, has been widely accepted as a 
measure of molecular lipophilicity. Lipophilicity affects both the pharmacokinetic and 
pharmacodynamic behavior of drug molecules (20,21). LogP considers the molecule 
in its neutral state (neutral substance or ionizable substance in its neutral form), 
whereas logD reflects the pH-dependent distribution coefficient, consequently taking 
the ionization of molecules into account. If logP and pKa of a compound are known, 
logD can be calculated at any pH (21). 
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The aqueous solubility (LogS) is closely related to drug stability, liberation, and 
absorption by passive diffusion, thereby playing a key role in its bioavailability (22). 
Causes for poor solubility are mainly excessive lipophilicity and crystal packing issue 
(23,24,25,26). The solubility of nonionic molecules is pH independent, while 
molecules with ionizable groups show pH dependent solubility. Acid drugs have 
higher solubility at pH higher than pKa and basic drugs at pH lower than pKa due to 
better solubility of ionic species as compared to the neutral species. The acid-basic 
character accounts also for crossing the blood-brain barrier (27). 
The polar surface area (PSA) of a molecule is a useful parameter for predicting 
drug transport properties. PSA is the sum of the molecular surface (either 
van der Waals or solvent-accessible) that arises from polar atoms, usually N, O, N-H, 
and O-H atoms. Some scientists also include sulphur and phosphor and attached 
hydrogens as polar atoms. The PSA of a compound is also closely related to its 
hydrogen bond accepting and donating ability which can be responsible for 
interactions with active efflux pumps (28,29). PSA has been shown to correlate well 
with blood-brain distribution (27,30,31), intestinal absorption (32,33,34,35,36,37), and 
oral bioavailability (38) of compounds. 
Table 1-4 Physicochemical parameters 
Parameter Description Predictor Optimal value
MW Molecular weight Size, Permeability < 500
< 450 (BBP)
LogP < 5
LogS Hydrophilicity > 20 µg/mL
pKa Acid-base character
PSA Polar surface area < 140 Å
< 80 Å (BBP)
Negative logarithm of 
the acid-base 
dissociation constant
Acids >4 and bases <10 
(BBP)
Permeability, H-
bonding capability
Logarithm of the 
octanol-water 
partition coefficient 
Lipophilicity, 
Permeability
Logarithm of the 
aqueous solubility
 
BBP: blood brain penetration 
1.3.2 Pharmacokinetic parameters 
The pharmacokinetic profile is crucial for the clinical success of drug candidates 
and their development into marketable drugs. Therefore, today the contribution of 
pharmacokinetic investigations to the selection and optimization of promising drug 
candidates is well recognized. The four most important parameters are clearance, 
volume of distribution, elimination half-life, and bioavailability, which is the fraction of 
drug absorbed as such into the systemic circulation (100% per definition for drugs 
given intravenously). 
Drug clearance (CL) expresses the rate or efficiency of drug removal from the 
systemic circulation and is estimated as the ratio of dose to AUC following 
intravenous administration of the drug: 
AUC
DoseCL =  
  
6
AUC is the total area under the curve that describes the concentration of drug in 
blood or plasma as a function of time. AUC represents the drug exposure and is 
calculated by the trapezoidal rule. 
The volume of distribution (V0) relates the amount of drug in the body to the 
concentration of drug in the blood or plasma, depending upon the fluid measured. 
This volume does not necessarily refer to an identifiable physiological volume, but 
merely to the fluid volume that would be required to contain all of the drug in the body 
at the same concentration as in the blood or plasma: 
o
iv
C
DoseV =0  
C0 represents the blood or plasma concentration at time zero and is determined by 
extrapolation to zero time of the linear plot of concentration vs. time in 
semilogarithmic scale. 
The half-life (t1/2) is the time it takes for the blood or plasma concentration or the 
amount of drug in the body to be reduced by 50%: 
kk
t
693.02ln
2/1 == , 
where k is the elimination rate constant, which can be calculated by the slope of the 
best-fit line to a semilogarithmic plot of the concentration over time. The relationship 
of t1/2 to both clearance and volume of distribution is given by: 
V
CLk =  
1.3.3 New trends in characterizing drug candidates 
Before conducting clinical trials in humans, preclinical testing is carried out to 
discover the pharmacology, ADME (adsorption, distribution, metabolism, and 
excretion), and toxicology of a new drug candidate (39). Appropriate 
pharmacokinetics and a good balance between drug efficacy and safety contribute 
mainly to an efficient and effective drug development. However, these factors are the 
major hurdles in development which primarily cause increased costs and failure rate 
of candidates. Thus, pharmaceutical industry needs new concepts able to speed and 
improve activities and decision-making in drug development (40,41). In this context, 
microdosing, biomarkers, and PET ligands can help to prioritize resources and 
optimize drug selection in development. In many cases, these approaches deal with 
compound concentrations ranging from sub-therapeutic to low pharmacological 
levels, and thus information obtained from these techniques must reflect correctly the 
conditions at therapeutic doses, including interactions with macromolecules like 
enzymes, transporters, and proteins. In the end, a successful integration requires a 
profound understanding of strengths and limitations of these new concepts. 
The administration of a low dosed (microdosed) drug candidate to humans was 
proposed to obtain human pharmacokinetic data before conducting Phase I trial (42). 
A microdose is one-hundredth of the proposed pharmacological dose determined 
from animal and/or in vitro models, or a dose up to 100 µg, whichever is the smaller 
(43). Human microdosing uses labeled agents administered mostly intravenously, 
and their fate in vivo is recorded by positron emission tomography combined with 
accelerator mass spectrometry or nuclear magnetic resonance (43,44). With this new 
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strategy of microdosing, drug information regarding human kinetics will be available 
along with preclinical data and can be useful for the acceptance or rejection of a 
candidate at an early stage. 
A biomarker is an indicator of a normal biological or pathophysiological process or a 
therapeutic response (45). Biomarkers help to select the most sensitive drugs in all 
phases of drug development (46) by providing data of pharmacological response, 
dosing regimen, and risk-benefit assessment. Therefore, efforts are moving rapidly 
forward to achieve strong predictive biomarkers which could be used for diagnostic 
and therapeutical purposes (47). 
PET tracers labeled with short-lived radionuclides (e.g. 11C, 18F, 124I) are used as 
molecular probes of physiology and pathophysiology in animals and humans. These 
labeled compounds are administered mostly intravenously at 600 MBq to humans 
which corresponds to 6-20 nmol (3-10 µg assuming a MW of 500) (48). To achieve 
the same imaging quality in animals, roughly the same total amount of 
radiopharmaceutical must be given to animals as to a human subject (49). 
1.4 Strategies and administration of intravenous formulations 
In the pharmaceutical industry, formulation scientists have faced growing 
challenges in recent years as a result of new drug candidates characterized as being 
more lipophilic, hydrophobic, and water-insoluble, particularly candidates originated 
from leads associated with combinatorial chemistry and high-throughput screening 
(16,24). In addition, timelines and resources are very limited to develop an optimized 
formulation and thus the search for a suitable dosing vehicle intended for activities in 
preclinical research represents a challenging task for the formulators (50). Ideally, it 
is best to select and use solubilizers that would maximize the solubility of the 
compound and could be applied for all preclinical settings. Moreover, the solubilizing 
agents should not influence the intrinsic pharmacokinetic characteristics of the 
compound being evaluated (except the interaction is well understood), which would 
lead to misinterpretation of the pharmacological response (51). Strategies for 
solubilization of intravenous drugs are summarized in Table 1-5 and well exemplified 
by the formulation approaches for the anticancer agent Paclitaxel (52). 
Usually, the first step is to check the solubility of the compound in an aqueous 
dosing vehicle at physiological pH and osmolarity. If the target concentration cannot 
be achieved with this approach and the drug molecule is ionizable, adjustment of the 
pH to non-physiological values can be suitable to increase water solubility (pKa must 
be sufficiently away from the formulation pH). Non-electrolytes are insensitive to pH 
modification. The next approach most frequently tried is the addition of water-
miscible organic solvents (cosolvents) and the use of surfactants or complexing 
agents. To reach the required dose, combination of these methods is often used. 
Dispersal systems are other techniques, but they may be difficult, costly, and time-
consuming due to biological and technical complexity, e.g. liposomes (53). 
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Table 1-5 Intravenous formulation approaches 
Approach Examples Administered in commercial productsa Potential drawbacks
NaCl 0.9% (w/v), pH 2-12 (bolus), pH 2-10 (infusion) Precipitation
Glucose 5% (w/v) → preferred range pH 4-9 Pain
Strong acids/bases (HCl, NaOH),
Buffers (tartarte, phosphate)
Cosolvents Propylene glycol ≤ 68% (bolus), ≤ 6% (infusion) Precipitation 
Ethanol ≤ 20% (bolus), ≤ 10% (infusion) Irritation/Pain
Polyethylene glycol 300 ≤ 50% (bolus) Hemolysis
Polyethylene glycol 400 ≤ 9% (bolus) Impact on PK profile
Surfactants Cremophor EL ≤ 10% (infusion) dito
Tween 80 ≤ 0.4% (bolus), ≤ 2% (infusion)
Solutol HS 15 50%
Complexing agents Hydroxypropyl-β-cyclodextrin 20% (infusion) dito
Dispersal systems: Impact on PK profile
Emulsionb/Microemulsionc Water with 10-20% oil (fatty acids + lecithin + glycerol) Sustained release
Liposomes Water with phospholipids (5-20 mg/mL) + isotonicifier + buffer ± cholesterol Instability
Nanosuspensiond Water with stabilizer not yet marketede Slow dissolution
Aqueous solution at physiological 
osmolarity and pH / or with pH 
adjustment
 
a(54), b(55), c(56), d(57), e(58) 
 
For compounds administered intravenously to animals, the dose volume, viscosity 
of injection material, speed of injection, and species are important factors to consider 
in addition to formulation properties including additives, solubility, and stability 
(Table 1-6) (59). A compound can be given over a short period of ≤1 min (bolus 
injection), 5-10 min (slow injection), and longer time period (intravenous infusion). 
Rapid injections require the dose to be compatible with blood and not too viscous, 
and the rate of injection is suggested not to exceed 3 mL/min for rodents. Depending 
on study objectives and compound solubility in an acceptable formulation, a larger 
volume may be needed to be given to animals to accomplish requirements. 
Regarding the formulation, aqueous solutions or simple systems containing 
cosolvent, surfactant, or complexing agent are recommended for animal 
investigations at early stage in development due to easy handling and 
characterization. For excipient selection, consideration should be given for toxic and 
biological effects, interferences with the drug compound, and suitability for clinical 
use (Table 1-5). Injectable excipients preferred for dosing in animals are: ethanol, 
propylene glycol, low molecular weight polyethylene glycols, Cremophor EL, 
Tween 80, and cyclodextrins. 
Table 1-6 Dose volumes and rates for intravenous administration(59) 
Species Bolus injection Slow injection Infusion 
  Volume Rate Volume Rate Time Volume Rat 
 (mL/kg) (mL/min) (mL/kg) (mL/min) (h) (mL/kg/d) (mL/kg/h) 
Mouse 5 3 max. 25 3 4   
 
    24 96 4 
Rat 5 3 max. 20 3 4 20 5 
     24 60 2.5 
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1.5 Effect of excipients on pharmacokinetic parameters in blood 
Over the last years, more attention has been paid to the extensive investigation of 
formulation vehicles as biologically and pharmacologically active compounds. The 
main stages in which pharmaceutical excipients can interact and hence may 
modulate the properties of an administered drug-agent are transporter, enzyme, and 
distribution process in the systemic circulation (e.g. plasma protein binding). The 
effect of excipients on transporter activity has been studied intensively, namely for 
P-glycoprotein (60,61,62,63,64,65,66,67,68), multidrug resistance-associated protein 
(69,70) and peptide transporter (71). It is interesting to say that particularly nonionic 
surfactants effectively inhibit transporters. In contrast, up to this day little is known 
about drug-excipient interactions at the level of cytochrome-mediated metabolism 
(63,72,73,74) and blood distribution (see below). The biological and pharmacological 
properties of excipients with a focus on the central blood compartment will be 
reviewed in the following paragraphs. 
1.5.1 Cremophor EL  
The amphiphilic polyethoxylated castor oil derivative Cremophor EL (CEL) is one of 
the most frequently used surface-active formulation ingredients in parenteral dosage 
forms. As early as 1977 lipoprotein alterations were observed  in patients receiving 
miconazole therapy (75) which was caused only by CEL, both in vitro and in vivo 
(76,77,78). Extended studies revealed later on that CEL has a destructive effect on 
HDL resulting in a shift of the electrophoretic and density gradient HDL to LDL 
(79,80,81,82). Furthermore, several hydrophobic anti-tumor agents, tin etiopurpurin 
(83,84), C8KC (85) and Taxol (81,82), showed strong affinity for these lipoprotein 
dissociation products inducing changes in plasma protein binding, potentially 
affecting pharmacokinetics. 
Various animal studies demonstrated (85,86,87,88,89,90,91,110) that CEL modifies 
the pharmacokinetic behavior of drugs after intravenous administration, like paclitaxel 
(Taxol), C8KC, and cyclosporin. The most common observation was a substantial 
increase in the area under the plasma concentration-time curve and in peak plasma 
concentration of studied agent with a reduction in the clearance, as was first 
described for paclitaxel in a mouse model (91). The drug-CEL interactions were 
supposed to be caused not only by altered protein binding characteristics (82), but 
also by altered hepatobiliary secretion (92) and endogenous P-glycoprotein-mediated 
biliary excretion (93). However, the very small volume of distribution of CEL, 
approximately equal to the volume of the central blood compartment, suggests that 
the observed interference occurs in the central blood compartment. This hypothesis 
was confirmed by studies recently published (94,95). The main finding was a 
profound alteration of cellular partitioning and blood/plasma concentration ratio of 
paclitaxel in a CEL concentration-dependent manner as a result of an entrapment of 
the compound into micelles formed by CEL (96). Consequently, the free drug fraction 
available for distribution was reduced. This effect was also observed in the absence 
of plasma proteins, pointing at contributing factors other than altered protein binding 
and increased affinity of paclitaxel for CEL-induced lipoprotein degradation products 
(81,82). 
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For the purpose of finding out a potential paclitaxel delivery vehicle with an ideal 
profile, the investigation of several delivery vehicles based on the chemical structures 
of CEL and Tween 80 led to alteration of blood distribution of paclitaxel in presence 
of all tested vehicles (97). Different formulation approaches such as liposomes and 
poloxamer-micelles affected the pharmacokinetics of paclitaxel in mice as compared 
to the CEL-containing formulation (98). In contrast, paclitaxel administered in a 
solvent-free formulation in a clinical study showed a higher efficacy combined with 
reduced adverse effects compared to the drug delivered in a solution of CEL (99). 
Overall, numerous investigations have shown that CEL can play a pivotal role in the 
pharmacological behavior of the formulated drugs. In addition, several drug-drug 
interactions are reported on agents administered intravenously in conjunction with 
CEL-containing formulation of other compounds, namely paclitaxel 
(100,101,102,103), cyclosporin (104,105,106,107), and valspodar (108,109). Most 
likely, the presence of CEL in drug formulations contributes to the observed 
pharmacokinetic interactions. Indeed, recent experiments revealed a substantial 
increase of plasma concentrations of cyclosporin after an additional injection of 
another drug preparation containing CEL (110). 
1.5.2 Cyclodextrins 
Cyclodextrins are ring-shaped oligosaccharides with a hydrophilic exterior and a 
hydrophobic interior (111). The interior cavity is capable of forming water-soluble 
complexes with many drugs. Due to the rapid release of a drug from the complex 
after administration in vivo, it is assumed that drug-cyclodextrin complexes do not 
affect the drug pharmacokinetics (112). However, if the drug is slowly or incompletely 
released from the complex, drug dosing as complexes in cyclodextrin can be critical. 
The binding of drugs to plasma proteins was influenced in vitro in the presence of 
β-cyclodextrin (113) and hydroxypropyl-β-cyclodextrin (HP-β-CyD) (114,115). The 
intravenous administration of flurbiprofen in HP-β-CyD led to transient higher tissue 
concentrations in rats (114). Alterations in tissue distribution were also found for 
other drugs injected as cyclodextrin complexes either free in solution (116,117) or 
included into liposomes (118). Following iv dosing in HP-β-CyD, a higher amount of 
carbamazepine appeared in the urine compared to oral preparations (122). A similar 
trend was observed in dogs treated iv with either dexamethasone formulated in 
HP-β-CyD or as its phosphate prodrug (123). In addition, cyclodextrins interacts with 
endogenous lipids such as lipoproteins (119,120) and cholesterol (113,121).  
1.5.3 Tween 80 
As mentioned above for CEL, lipoprotein alteration induced by Tween 80 was 
observed (80). However, this effect was not confirmed in a further study (85). In 
patients receiving Tween 80 co-administered with etoposide, an increase of the 
volume of distribution and the clearance of doxorubicin was detected due to reduced 
plasma concentrations of doxorubicin during the early phase of the concentration-
time profile (124). Lately, changes in the blood/plasma ratio of paclitaxel were 
described in the presence of Tween 80 and other solubilizers structurally related to 
Tween 80 (97). More recently, it was shown that Tween 80 has a concentration-
dependent influence on the normal binding of docetaxel to serum proteins leading to 
changes in pharmacokinetics of docetaxel in vivo (125) although Tween 80 is 
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degradated rapidly by esterases in plasma (126). The mechanistic basis for altered 
plasma binding of docetaxel in the presence of Tween 80 still needs to be clarified. 
1.5.4 Other excipients 
To date, little is reported in the literature about the impact of Solutol HS 15 and 
Poloxamer 188 on blood distribution of drugs. An interference between Solutol HS 15 
and the co-administered ketochlorin photosensitizer C8KC was suggested by 
Woodburn (127). The similar half-lives of Solutol HS 15 and the sensitizer found in 
mice indicate the correlation of the persistence of C8KC in plasma with that of the 
vehicle. Further, recent plasma protein binding interaction studies demonstrated an 
apparent increase in the unbound fraction of propranolol in combination with 
Poloxamer 188 (128). Also the administration of compounds formulated in mixed 
micelles can alter the protein binding (129). Most notably compounds binding with 
high affinity but low capacity to α1-acid glycoprotein showed free fractions increased 
by 50 to 85%. Moreover, blood protein interactions can occur with dosing vehicles 
like liposomes (130), thereby affecting maybe the fate of co-administered drugs in 
blood and body (131). 
1.5.5 Nanoparticles 
Methyl methacrylate nanoparticles of 130 nm in size suspended in different 
concentrations (0.1-5%) of Tween 80 or poloxamine 908 exhibited prolonged 
circulation time with altered tissue concentrations as compared to uncoated 
nanoparticles (132). Extended blood circulation time was also found for polystyrene 
nanoparticels (40-137 nm) coated with poloxamer 407 (133). 
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1.6 Objectives and specific aims 
The main purpose of this thesis was to investigate in vitro drug-excipient 
interactions in blood and to assess the implications of the in vitro findings both for the 
in vivo situation and the formulation strategy. Compounds in drug development at 
Novartis were chosen as model substances and dosed at concentrations ranging 
from sub-therapeutic to low pharmacological levels. Excipients commonly used in 
formulations were selected, including CEL, HP-β-CyD, Solutol, PEG 200, and TPGS. 
The following specific aims of the thesis were: 
 
1. To collect and use available compound information, including physicochemical 
properties and pharmacokinetics, to select appropriate model substances with 
as many different properties as possible 
2. To determine the hemolytic activity of selected excipients to rule out any 
changes of blood distribution caused by hemolysis 
3. To explore in vitro possible effects of selected excipients in the blood, with 
special emphasis on the blood distribution and plasma protein binding of model 
compounds 
4. To identify the pharmacokinetic profile and tissue distribution of model 
compounds following single intravenous dosing in the presence and absence of 
selected excipients 
5. To compare and relate pharmacokinetic outcomes to the in vitro findings, 
thereby assessing the impact of in vitro data for the in vivo situation and 
evaluating the in vitro-in vivo correlation 
6. To generate criteria for optimizing delivery vehicle selection in drug research 
that allow reducing drug-excipient interactions and leading to more rational and 
selective drug formulations 
7. To propose an intravenous formulation strategy based on the data generated by 
this research project to provide better candidate-tailored formulations in drug 
development 
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2 Selection and experimental procedure 
2.1 Excipients and model compounds 
Investigations involved five excipients along with five pharmacologically active 
compounds exhibiting different properties. 
The excipients CEL, HP-β-CyD, Solutol, and PEG 200 were selected based upon 
their common use in intravenous formulations and their diversity of molecular 
structure and solubilization technique (Figure 2-1 and Table 2-1). CEL and Solutol 
are surface-active agents which increase the drug solubility by incorporation of the 
drug into a micellar structure. Whereas CEL exhibit a highly variable composition with 
the major hydrophobic component (~87%) identified as oxyethylated triglycerides of 
ricinoleic acid (Figure 2-1), Solutol consists of ~70% lipophilic polyglycol mono- and 
di-esters of 12-hydroxystearic acid and ~30% hydrophilic polyethylene glycol. 
HP-β-CyD is a cyclic (α-1,4)-linked oligosaccharide containing seven α-D-gluco-
pyranose units (Figure 2-1) which form a relatively hydrophobic central cavity and a 
hydrophilic outer surface. The inclusion of a drug within the inner core of the 
complexing agent and the interaction of the outer core with water render the complex 
soluble. PEG 200 is often used as a cosolvent for improving solubility of preclinical 
compounds by interrupting the hydrogen structure of water (e.g. water exclusion) and 
lowering the dielectric constant of the solution. Although TPGS is exclusively known 
in oral formulations, it was chosen due to its chemical structure (benzyl ring) and 
drug interaction potential at the level of active transporters and metabolizing enzyme 
systems. 
 
Cremophor EL 
H2C(CH2CH2O)xOCO(CH2)7CH CHCH2CHOH(CH2)5CH3
HC(CH2CH2O)yOCO(CH2)7CH CHCHCH2CHOH(CH2)5CH3
H2C(CH2CH2O)zOCO(CH2)7CH CHCH2CHOH(CH2)5CH3
 
 
primary constituent with x + y + z ~35 
Solutol HS 15 
CH3 (CH2)5 CH (CH2)10 C O CH2 CH2 OH
n
 
OH O
 
 
 
Polyethylene glycol 200  
O
HOH
n
 
 
Hydroxypropyl-β-cyclodextrin 
O
ROCH2
O
RO
OH
n
 
 
glucopyranose with R=CH2CH2OH or H and n=7 
Vitamin E TPGS 
O
O C CH2 CH2 C O
O O
CH3
CH3
OH n
 
CH3
CH3
CH (CH2)3
CH3
CH (CH2)3 CH(CH2)3
 n=20-22 
Figure 2-1 Chemical structures of selected excipients 
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Table 2-1 Properties of selected excipients 
Excipient name Type Solubilization Use in iv  Biological activity 
 
 
approach formulation  
Cremophor EL Non-ionic  Micelles Yes • Dyslipidaemia 
(polyoxyethylene  surfactant  (developmental • Inhibition of active 
castor oil derivatives)   & commercial) transporters 
MW ~3000     
CMC ≥0.09 mg/mL     
Hydroxypropyl-β- Oligomeric  Complexation Yes • Lipid interactions 
cyclodextrin substance  (developmental  
MW ~1600   & commercial)   
Solutol HS 15 Non-ionic  Micelles Yes • Dyslipidaemia 
(polyethyleneglycol 660 surfactant  (developmental • Inhibition of active 
12-hydroxystearate)   & commercial) transporters 
MW 960    • Inhibition of cyto- 
CMC ≥0.2 mg/mL    chrome enzymes 
Polyethylene glycol 200 Oligomeric  Cosolvent Yes  
MW ~200 substance (change of (developmental  
  solution & commercial*)  
  polarity)   
Vitamin E TPGS Non-ionic  Micelles No  • Inhibition of active 
(D-α-tocopheryl  surfactant  (oral use: transporters 
polyethylene glycol 1000   developmental • Inhibition of cyto- 
succinate)   & commercial) chrome enzymes 
MW ~1513     
CMC ≥0.2 mg/mL      
CMC: Critical micelle concentration, MW: Molecular weight, *: Higher molecular weight PEGs such as PEG 300 and 400  
 
Drug candidates in development at Novartis were chosen as model compounds 
regarding aqueous solubility, lipophilicity, membrane permeability, and 
blood cell/plasma distribution (Figure 2-2 and Table 2-2). COM2 and COM1 (base) 
are lipophilic and poorly water-soluble PET ligands which are used in sub-therapeutic 
doses, and COM2 distributes equally between plasma and whole blood. COM3 is 
much better water-soluble and is mainly located in the cellular fraction in blood. In 
contrast, COM4 with a low lipophilicity penetrates hardly into blood cells and 
distributes poorly into tissues. COM5 is a bigger molecule characterized by a high 
polar surface area, many H-bond acceptors, and a very low volume of distribution 
similar to that obtained for COM4. 
 
COM1 COM2 COM3 COM4 COM5 
N
N
O
R1
R2
 
 
O
N
O
N
N
S
R1
R2
 
N
O
N
R
 
N
N
R2
R1
 
N
NO
S O
N
H
O
O
NH
OR1
R2
R3
 
Figure 2-2 Chemical structures of model compounds 
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Table 2-2 Properties of model compounds 
Physicochemical (PC) and pharmacokinetic (PK) data available at the time of selecting model 
compounds for investigating drug-excipient interactions in blood. 
 
COM1 COM2 COM3 COM4 COM5 
 
PET ligand PET ligand NCE NCE NCE 
PC properties 
     
MW (g/mol) 240 410 295 <400 533 
LogD 6.8 3.4 4.5 2.3 1.7 3.7 
pKa 3.8 5.7 4.1, 8.7 3.2, 4.6 10.6 
H2O solubility, pH 6.8 (mg/L) 20 <2.5 4000 <500 100 
PSA (Å2) 35 50 25 63 166 
H-bond acceptors 3 5 3 4 12 
H-bond donors 0 0 0 1 3 
PK properties 
     
Species  Mouse Rat Rat Rat 
In vitro 
     
Fraction in plasma (%)  45 20 ~100 80 
Free in plasma (%)   12 2.4 11 
In vivo 
     
Matrix 
 Blood Blood Plasma Plasma 
t1/2 (h)  1.1 1.1 10 0.4 
CL (mL/min/kg) 
 10 142 0.4 7.2 
Vss (L/kg)  14 10 0.3 0.3 
funchanged (%)  49 14 98 94 
Main selection criteria • Active  • Active  • Blood  • Blood • MW 
 principle principle distribution distribution • Polarity 
 • H2O sol. • H2O sol.  • Vss • Vss 
 (base) • Lipophilicity     
funchanged: Fraction of unchanged drug based on AUC ratio of parent drug and total radioactivity, LogD: Logarithm of 
octanol-water distribution coefficient, MW: Molecular weight, NCE: New chemical entity, pKa: Negative logarithm of 
dissociation constant, PSA: Polar surface area, CL: Drug clearance, t1/2: Main elimination half-life, Vss: Volume of distribution 
under steady-state conditions 
2.2 Experimental setup 
The effect of excipients on pharmacokinetic parameters was examined in rats 
except for COM2 which was investigated in mice due to available animal models 
appropriate to analyze drug target interactions if required. Model compounds were 
used in their clinically relevant blood range as follows: sub-therapeutic (<5 ng/mL) for 
COM1 and COM2, low-therapeutic (5-50 ng/mL) for COM3, and therapeutic 
(>50 ng/mL) for COM4 and COM5 because of low distribution volumes to assure 
detectable tissue concentrations. To allow in vitro and in vivo study comparisons, the 
amount of excipient in blood was set at ~0.5% which is within the range after an iv 
bolus injection in mice and rats. 
Blood distribution and protein binding studies were done in vitro using model 
compounds in the appropriate concentration range with and without selected 
excipients fixed at 0.5% in the test system. Since COM4 is almost completely located 
in the plasma fraction in blood (FP ~100%) independent of the concentration 
(10-10’000 ng/mL) (149), the concentration of COM4 was kept constant (100 ng/mL), 
whereas the excipient amount was varied between 0.01-1%. Compounds formulated 
as excipient-free solution in glucose 5% or saline served as reference. The excipient 
with the most prominent effect compared to the reference was selected for the in vivo 
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study where animals received intravenously a single dose as a control formulation or 
solution containing the selected excipient. Control formulation were based on 
glucose 5% (COM1, COM3), saline (COM4, COM5), or blank plasma (COM2). To 
assure a fast and complete solubility of COM3 and COM5 in the control formulation, 
convenient excipients were added with in vitro binding parameters similar to those 
obtained for the in vitro reference. The concentration of model compounds in blood, 
plasma, and tissue were measured until 1 h after iv administration, thereby including 
the scanning time of PET ligands. Moreover, it is assumed if excipient-induced 
changes occur they should be detectable in this time period. 
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3 Materials and methods 
3.1 Chemicals 
COM1 and COM2 were supplied by the Neuroscience Research Department of 
Novartis (Basel, Switzerland). COM3 was obtained from the Novartis Institutes for 
BioMedical Research (Basel, Switzerland). 3H-radiolabeled COM1 (specific activity 
11780 MBq/mg, >99%), COM2 (specific activity 2320 MBq/mg, >98%), and COM3 
(base, specific activity 31.1 MBq/mg, >98%) were provided by the Isotope 
Laboratories of Novartis (Basel, Switzerland). 14C-radiolabeled COM3 used for 
investigation of renal excretion (2·HCl salt, specific activity 5.87 MBq/mg, >98%), 
COM4 (specific activity 5.85 MBq/mg, >98%), and COM5 (specific activity 
3.3 MBq/mg, >98%) were provided by the Isotope Laboratories of Novartis (Basel, 
Switzerland). 
The excipients, purchased by the Pharmaceutical and Analytical Development 
Department of Novartis (Basel, Switzerland), were: Cremophor EL (CEL; BASF), 
hydroxypropyl-β-cyclodextrin (HP-β-CyD; CERESTAR USA Inc.), polyethylene 
glycol 200 (PEG 200; Fluka), Solutol HS 15 (Solutol; BASF), and D-α-tocopheryl 
polyethylene glycol 1000 succinate (TPGS; Eastman). All other chemicals and 
reagents were of analytical grade or will be described separately in the methods 
section. 
3.2 Blood and plasma sources  
Fresh blood was obtained from healthy male species (n≥3) as follows: mice 
(albino OF1, Charles River Laboratories, L’Arbresle, France), rats (Wistar HAN IGS, 
Charles River Laboratories, Sulzfeld, Germany), dogs (Marshall beagles, Marshall 
Farm, NY, USA and Harlan France SARL, Gannat, France), and humans (drug-free 
blood donors, Blutspendezentrum SRK Basel, Switzerland). Pooled plasma (n≥3) 
was defrosted from storage at -20°C. Lithium heparin was used as an anticoagulant 
for all species. 
3.3 In vitro studies 
Test compounds in the in vitro samples excluding protein binding samples of COM2 
were quantified by LSC due to no major degradation (>95%) under investigated 
conditions (146,147,148,149,150). Protein binding samples of COM2 were quantified 
by LC-RID due to instability after longer incubation (>2 h) and very low fraction 
unbound in plasma (<2%). 
3.3.1 Preparation of test solutions 
For in vitro blood distribution and protein binding studies, test solutions were 
prepared by dissolving the radiolabeled test compound in ethanol. Ethanol was 
evaporated and the residue was reconstituted in the appropriate formulation, namely 
excipient-free solution as control (saline or glucose 5%) and solutions containing 
CEL/EtOH 65:35 (v/v), CEL, HP-β-CyD, Solutol, PEG 200, and TPGS. Final 
compound concentrations in blood or plasma were: 0.06-6 ng/mL (COM1), 
0.01-100 ng/mL (COM2), 5-500 ng/mL (COM3), 100 ng/mL (COM4), and 
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10-300 ng/mL (COM5). Excipient concentrations were kept constant at 0.5% in the 
test system except for COM1 (0.5-5% due to no alterations at 0.5%) and COM4 
(0.01-1% due to its plasma fraction, see 2.2). 
3.3.2 Hemolytic activity 
The hemolytic activity of the excipients was assayed using a spectrophotometric 
method. CEL/EtOH 65:35 (v/v), EtOH, HP-β-CyD, PEG 200, Solutol, and TPGS were 
added to the appropriate volume of freshly prepared heparinised whole blood to 
obtain a final excipient concentration of 0.5%. To avoid hemolysis due to higher 
concentrations during the adding, the blood was partially centrifuged and the 
excipient was pipetted in the cell-free layer. By tapping the test tubes, the samples 
were immediately mixed. Two control tubes were prepared, one for spontaneous 
hemolysis (pure blood used as the reaction blank) and another for 100% hemolysis 
(total cell lysis induced by sodium dodecyl sulfate at a final blood concentration of 
1%). Samples were incubated at 37°C. At certain points of time, aliquots were 
removed and centrifuged for 10 min at 3100 x g (37°C) to obtain plasma. The 
absorbance of hemoglobin in the supernatant (dilution with water 1:200) was 
measured at 405 nm (Emax precision microplate reader, Bucher Biotech, Basel, 
Switzerland). The degree of hemolysis due to the excipient activity was calculated 
according to 
100(%)
0100
0 ×
−
−
=
AA
AA
Hemoylsis e  
where Ae is the absorbance of hemoglobin in the supernatant after incubation with 
excipient, A0 is the absorbance of hemoglobin in the supernatant of the reaction 
blank, and A100 is the absorbance of hemoglobin in the supernatant after total cell 
lysis with sodium dodecyl sulfate. Hemolytic activity was considered to have started 
when mean values were greater than 2% of hemolysis. 
3.3.3 Blood distribution 
Freshly prepared heparinised blood was used, and experiments were performed in 
triplicate both in the presence and absence of excipients. The hematocrit was 
determined using a hematocrit centrifuge and a hematocrit reader (Haemofuge 
Heraeus Sepatech, Germany). In order to reduce hemolysis, blood aliquots (1 mL) 
were partially centrifuged (500 x g for 2 min) before adding the test solution in the 
cell-free layer, followed by mixing immediately. Samples were incubated at 37°C. 
Time aliquots (1 mL) were removed and prepared for measuring radioactivity of the 
test compound in whole blood before centrifugation and in plasma after centrifugation 
for 10 min at 3100 x g (37°C) by LSC. 
The fraction of the test compound in plasma (FP) was calculated according to 
100)1((%) ×−×=
B
P
P C
HC
F  
where CB and CP are the drug concentration in blood and plasma respectively, and H 
is the hematocrit value. The concentration in blood cells (CBC) was calculated as 
follows: 
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and used for calculations of blood cell to plasma concentration ratio (BCPR: CBC/CP) 
and blood cell to unbound in plasma concentration ratio (ρ: CBC/(CP*fu)). fu is the 
drug fraction unbound in plasma determined by the appropriate protein binding 
method for each compound. 
3.3.4 Plasma protein binding 
Control experiments in phosphate buffered saline (PBS, Gibco, Paisley, Scotland) 
were carried out to assess the suitability of the methods described below for each 
test compound in the following order: ultrafiltration > dialysis > ultracentrifugation, 
with ultrafiltration being the first procedure. Control experiments indicated that 
ultrafiltration is a suitable method for COM1, COM3, COM4, and COM5 (free-
permeation >0.75, recovery >85%) and ultracentrifugation for COM2 (no 
sedimentation after 6-h centrifugation, recovery >85%; ultrafiltration and dialysis 
showed insufficient recovery and free-permeation). Therefore, protein binding was 
determined by the ultrafiltration technique (COM1, COM3, COM4, and COM5) or the 
ultracentrifugation technique (COM2). 
Ultrafiltration 
Samples of spiked plasma were incubated at 37°C until binding equilibrium. 
Aliquots of 1 mL were introduced in prewarmed (37°C) Centrifree micropartition tubes 
(Amicon Inc., Beverly, MA, USA) and centrifuged for 10 min at 2000 x g (37°C). For 
the determination of the unbound drug fraction in plasma, concentrations of the test 
compound in ultrafiltrate and plasma were measured. The unbound fraction in 
plasma (fu) was calculated as follows: fu(%)=(CUF/CP)x100, where CUF and CP are 
the drug concentration in ultrafiltrate and in plasma, respectively. 
Equilibrium dialysis 
Test solution was added to plasma followed by mixing. Dialysis was carried out with 
150 µL of this sample against an equal volume of phosphate-buffered saline (pH 7.2) 
in a 96-well micro-equilibrium dialysis block (HTDialysis LLC, Gales Ferry, CT, USA). 
Dialysis membranes with a 12000-14000 molecular weight cut-off were soaked in 
phosphate buffered saline (pH 7.2) before use. After establishment of the equilibrium, 
buffer solution aliquots, containing only unbound drug, and plasma aliquots, 
containing both bound and unbound drug, were analyzed for the test compound. The 
ratio of drug concentrations measured in the buffer and plasma after dialysis was 
taken as an estimate of unbound drug fraction in plasma. 
Ultracentrifugation 
Samples of spiked plasma were incubated at 37°C until binding equilibrium. 
Aliquots of 1 mL were transferred to polycarbonate centrifuge tubes (Beckman) and 
either centrifuged in a TLA 100.2 rotor in Beckman TL 100 centrifuge (200000 x g, 
6 h, 37°C) or incubated for 6 h (37°C). After centrifugation, samples were separated 
into three layers according to density. A 80-µL aliquot of the middle layer (protein-free 
part/plasma water) was taken and analyzed for the test compound, representing the 
unbound concentration in plasma (CU). Total plasma concentration (CP) was 
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determined in incubated samples. The unbound drug fraction in plasma was 
calculated using CU/CP. 
Determination of major binding protein 
The affinity of test compounds to different plasma proteins was determined using 
the appropriate method for each compound. Purified human plasma proteins were 
dissolved in phosphate buffered saline (PBS, Gibco, Paisley, Scotland) at 
physiological concentrations as follows: albumin 40 g/L (≥96%, Sigma), α-acid 
glycoprotein 1 g/L (from Cohn Fraction VI, 99%, Sigma), γ-globulins 12 g/L (from 
Cohn Fraction II and III, Sigma), high density lipoprotein 3.9 g/L (>95%, Calbiochem), 
low density lipoprotein 3.6 g/L (>95%, Calbiochem), and very low density lipoprotein 
1.3 g/L (>95%, Calbiochem). Test solution was added to protein solutions to obtain a 
compound concentration of 10 ng/mL (COM1, COM2) or 1000 ng/mL (COM3, COM4, 
COM5). After incubation at 37°C, separation of bound and unbound compound was 
achieved according methods. Ultrafiltration was performed by centrifugation for 
10 min for samples containing albumin and γ-globulins and for 2 min for all other 
samples. 
3.3.5 Determination of protein concentration 
Protein concentration was measured by the method of Bradford (Coomassie blue 
protein assay) at 595 nm by using a Bio-Rad protein assay (Bio-Rad Laboratories, 
München, Germany). The protein concentration was determined by using a 
calibration curve that was established with known concentrations of human serum 
albumin (≥96%, Sigma) ranging from 0 to 0.5 mg/mL. 10-µL aliquots of plasma 
(1:200 dilution) and plasma water were pipetted into microtiter plate wells. 200 µL 
dye reagent were added, and samples were mixed. After 1-h incubation at room 
temperature, absorbance was measured. 
3.4 In vivo studies 
Samples collected after intravenous administration of COM1, COM2, and COM3 
were assayed for radioactivity by LSC and parent drug by LC-RID. COM4 and COM5 
were quantified in all in vivo samples only by radioactivity measurements (LSC) since 
the radioactivity of both radiolabeled compounds reflects well the parent drug due to 
no major degradation at 1 h after intravenous administration in rats (151,152). 
3.4.1 Experimental animals 
Male Wistar rats (~250 g) and male OF1 mice (~30 g) were obtained from Charles 
River (Sulzfeld, Germany). All animals were housed in standard cages in a controlled 
environment maintained on an automatic 12-h lighting cycle at a temperature of 22°C 
according to institutional guidelines. The animals were given a standard chow and 
water ad libitum. The animals were used after having been starved overnight. 
3.4.2 Drug administration and sample collection 
All dosing solutions were prepared within 1 h prior to injection and stored at room 
temperature until use. Administration was performed by a single bolus injection into 
the femoral vein after animals had been lightly anesthetized by isoflurane (Forene®). 
Rats received [3H]COM1 at 4 µg/kg as solution (1 mL/kg) in glucose 5% containing 
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ethanol 1% (v/v) or TPGS 20% (w/v). Mice were injected a dose of 400 ng/kg of 
[3H]COM2 formulated as solution (5 mL/kg) in blank plasma (obtained by 
centrifugation of freshly drawn mouse blood) or in glucose 5% containing 
TPGS 10% (w/v). An iv dose of 1 µmol/kg radiolabeled COM3 (3H: 300 µg/kg, 
14C: 370 µg/kg) in EtOH/PEG200/Glu 5:5:90 (v/v/v) or 40% HP-β-CyD (w/v) was 
injected to rats (1 mL/kg). [14C]COM4 was administered at 400 µg/kg in saline or 17% 
CEL (v/v) to rats (2 mL/kg). [14C]COM5 at 1 mg/kg in saline containing either ethanol 
10% (v/v) or 17% Solutol (w/v) were injected to rats (2 mL/kg). 
Using these injection preparations, excipient concentrations in blood may be 
estimated as about 0.3% (COM1), 0.5% (COM3, COM4, COM5), and 0.7% (COM2) 
in animals (~70 mL blood/kg). These concentrations were similar to those used in the 
in vitro experiments. 
Samples were collected after drug administration at 0.08, 0.25, and 0.5 h for COM1 
and at 0.08, 0.25, 0.5, and 1 h for COM2, COM3, COM4, and COM5. Animals (n=3 
per time point) were sacrificed by isoflurane inhalation for sample collection. Blood 
samples were collected from the vena cava and transferred into tubes containing 
heparin (heparin-Na, B.Braun) as anticoagulant. Plasma samples were obtained by 
immediate centrifugation of blood samples at 3000 x g for 10 min. Tissues were 
excised, blotted dry, and weighed. Collected tissue comprised lung, heart, liver, 
kidney, fat, muscle, skin, and brain for COM1, COM2, COM3 and lung, muscle, and 
skin for COM4 and brain, muscle, and skin for COM5. All samples were immediately 
frozen and stored at -20°C until analysis. Tissue samples were homogenized before 
quantification. 
3.4.3 Bladder catheterization and urine collection 
The experiment was performed in situ under anesthetized rats. Animals 
(n=3/formulation) received im injections of ketamine hydrochloride at a dose of 
50 mg/kg (100 mg/mL, 0.5 mL/kg) and are positioned on an isothermal heating pad 
prewarmed at 38°C. The abdomen was opened through a mid-line incision. A 
polyethylene tubing (Clay-Adams PE-50) was inserted into the dome of the bladder 
and held in place with a purse string suture. The formulation was injected into the 
surgically exposed femoral vein, and urine was collected at 0.5, 1, 1.5, and 2 h after 
dosing. All samples were frozen and stored at -20°C until analysis. 
3.4.4 Ex vivo protein binding 
Ex vivo protein binding was determined for COM1, COM3, COM4, and COM5 
according to the in vitro procedure. Briefly, remaining plasma samples of each time 
point were pooled, and the unbound drug concentration in plasma was quantified 
using the ultrafiltration technique (see 3.3.4). After centrifugation, plasma and 
ultrafiltrate samples were assayed for radioactivity by LSC and parent drug by 
LC-RID. 
3.5 Measurement of the radioactivity 
Aliquots of blood, plasma, urine (25-50 µL) and homogenates (250 µL) were 
introduced into counting vials and solubilized in Biolute-S (Zinsser Analytic). Samples 
obtained from in vivo studies containing tritium-labeled drug were dried, and the 
residue was reconstituted in water before solubilization. To the blood samples, 
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hydrogen peroxide 30% was additionally added, and vials were gently swirled for 
several seconds and let stand for 30 min. After adjusting pH >7 by addition of 
hydrochloric acid 2 N, the vials were filled with scintillation cocktail (Irgasafe Plus, 
Zinsser Analytic), kept in the dark for 16 h, and measured in a Tri-Carb liquid 
scintillation spectrometer Model A2200 (Packard). 
3.6 Determination of parent drug 
3H-radiolabeled COM1, COM2, and COM3 were determined by a liquid 
chromatography-reverse isotope dilution method (LC-RID). A sample aliquot 
(100-500 µL) and 200 µL water containing 5 µg (COM1, COM3) or 2 µg (COM2) 
non-radiolabeled test compound as internal standard was added to a glass tube. 
After further addition of 1 mL water, 100 µL Titrisol buffer (pH 4: COM1, COM2; 
pH 7: COM3), and 4 mL diethyl ether (COM1, COM2) or tert-butylmethylether 
(COM3), tubes were shaken for 30 min and centrifuged (3300 x g for 10 min). The 
organic layer was collected in another glass tube and evaporated in a vacuum 
centrifuge (Univapo 150H, UniEquip, Martinsried, Germany). The residue was taken 
up in 250 µL of mobile phase-water (80:20, v/v) and 75 µL n-hexane, and the mixture 
was transferred in an auto sampler glass vial. After centrifugation (13000 x g for 
2 min), the hexane layer was discarded, and 200 µL of the remainder was injected 
into the HPLC system equipped with a Supelcosil LC-18 column (5 µm, 4.6 mm x 
150 mm) for COM1 or Waters XTerra RP 8 column (5 µm, 3.9 x 150 mm) for COM2 
and COM3. The column temperature was 40°C, and the absorbance was detected at 
a wavelength of 312 nm (COM1), 441 nm (COM2), or 261 nm (COM3). The mobile 
phase (isocratic gradient) consisted of ammonium acetate 10 mM-acetonitrile (45:55, 
COM1; 50:50, COM2) or ammonium acetate 10 mM-triethylamine 0.1% in acetonitrile 
(58:42, COM3) and was pumped at a rate of 1.0 mL/min. The peak corresponding to 
the unchanged compound was collected in a polyethylene vial by a fraction collector 
(Pharmacia LKB SuperFrac) and analyzed for radioactivity. Concentrations of the test 
compound in samples were calculated from the ratio of the amount of radioactivity in 
the eluted fraction and the area of the absorbance of the non-radiolabeled test 
compound used as internal standard. 
3.7 Data analysis 
Total radioactivity concentrations, expressed as ng-eq/mL or ng-eq/g, were 
estimated by dividing the radioactivity concentration in samples by the specific 
radioactivity of administered test compound using Microsoft Excel. Concentrations of 
parent drug were determined by the principle of reverse isotope dilution using 
following equation in Microsoft Excel 
ID
AD
IS
AS
A
A
A
A
=  
where AAS is the amount of analyte in the sample (unknown, to be determined), AIS is 
the amount of internal standard added to the sample, AAD is the amount of analyte 
detected, and AID is the amount of internal standard detected. AAD was calculated 
using R/(SRxS) where R is the amount of radioactivity determined in the peak 
fraction, SR is the specific radioactivity, and S is the slope. The amount of internal 
standard detected was calculated as AID=Area/RF-AAD where RF is the response 
factor (Area/ng). The level of quantification (LOQ) was set to 75 dpm. LOQs of 
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radioactivity and test compound in blood, plasma, urine, and tissues were calculated 
by dividing 75 dpm by the specific radioactivity of the administered test compound 
and by the sample amount. P values were calculated with a two-sample t-test in 
Microsoft Excel assuming unequal variances. The level of significance was set at 
P <0.05. 
3.8 Pharmacokinetic analysis 
Pharmacokinetic parameters were estimated as follows: The area under the drug 
concentration-time curve (AUC) was determined by the linear trapezoidal rule using 
the mean data points. The half-life (t1/2) was calculated using ln2/k, where k is the 
rate constant. k was estimated by the slope of the regression line plotted through the 
three final data points of the semilogarithmic AUC, taking into consideration a square 
of correlation coefficient of RSQ >0.90. Volume of distribution (V0) was calculated by 
dividing the dose by the concentration at time zero (C0). C0 was obtained by 
extrapolation to zero time of the concentration-time plot in semilogarithmic scale. 
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4 Results and discussions 
4.1 Hemolytic activity of excipients 
In vitro results  
CEL/EtOH 65:35, EtOH, HP-β-CyD, PEG 200, and Solutol did not induce hemolysis 
in dog and human blood at 0.5% and a contact time of 4 h (data not shown). In 
contrast, TPGS at 0.5% incubated with blood of various species caused hemolysis in 
a time-dependent manner (Figure 4-1). Erythrocytes from rat and human were more 
sensitive than those of mouse and dog, indicated by cell lysis at shorter contact 
times. Reducing the TPGS concentration from 0.5% to 0.1% induced no hemolysis in 
all four species in the investigated time range (data not shown). 
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Figure 4-1 Effect of incubation time on the hemolytic activity of TPGS 
Induced hemolysis by 0.5% TPGS in blood of various species (n=3, mean ± SD). Hemolysis in rat 
blood after 6-h incubation was not determined. 
Discussion  
Except for TPGS, all tested excipients (CEL, EtOH, HP-β-CyD, Solutol, and 
PEG 200) were non-hemolytic which is consistent with data reported in the literature 
(134,135,136,137,138) and the fact that they are widely used in commercially 
available parenteralia (54). TPGS at 0.5% exhibited marked hemolysis after longer 
contact time (>1 h), whereas TPGS at 0.1% showed no hemolysis under equal 
incubation conditions. The detected hemolysis might possibly result not mainly from 
TPGS but from metabolites, namely α-tocopheryl succinate and polyethylene glycols, 
both being able to destruct erythrocytes (134,139,140). This phenomena could 
contribute to the extensively delayed onset of hemolysis. For the investigations, 
TPGS at 0.5% was used in the non-hemolytic time range. 
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4.2 Impact of the hematocrit on blood partition parameters 
In vitro results 
Whole blood derived from three species was incubated with COM2 (100 ng/mL) at 
varying hematocrit values. Concentrations of COM2 in blood and plasma were 
measured at equilibrium, and partition parameters calculated from these data are 
summarized in Table 4-1. Concentrations in blood, plasma, and blood cells remained 
unaffected by the hematocrit value (0.40-0.60). The partition parameter BPR was 
also similar over the investigated hematocrit range, whereas BCPR changed slightly 
and FP distinctly, both decreasing by increasing the hematocrit from 0.40 to 0.60. 
Table 4-1 Effect of hematocrit on the in vitro blood distribution of COM2  
Blood cell concentrations and partition parameters (FP, BPR, and BCPR) derived from [3H]COM2 
concentrations measured in blood and plasma using same blood pools at different hematocrit values 
(n=3, mean ± SD). 
Species Hematocrit Concentration (ng/mL) FP BPR BCPR 
  
  Blood Plasma Blood cells (%)     
Mouse 0.40    50 ± 1 1.21 ± 0.03 1.52 ± 0.07 
 0.45    46 ± 2 1.20 ± 0.06 1.44 ± 0.13 
 0.50 101 ± 3 87 ± 4 116 ± 8 43 ± 0 1.16 ± 0.01 1.32 ± 0.01 
 0.55    40 ± 1 1.13 ± 0.04 1.23 ± 0.06 
  0.60       36 ± 1 1.12 ± 0.03 1.19 ± 0.05 
Dog 0.40    48 ± 2 1.26 ± 0.06 1.66 ± 0.14 
 0.45    44 ± 1 1.25 ± 0.04 1.57 ± 0.09 
 0.50 109 ± 4 90 ± 2 131 ± 15 41 ± 1 1.25 ± 0.03 1.51 ± 0.05 
 0.55    38 ± 1 1.19 ± 0.03 1.35 ± 0.06 
 0.60    35 ± 1 1.13 ± 0.02 1.22 ± 0.03 
Human 0.40       70 ± 3 0.86 ± 0.03 0.66 ± 0.08 
 0.45    65 ± 2 0.84 ± 0.03 0.65 ± 0.07 
 0.50 101 ± 5 125 ± 10 78 ± 6 63 ± 2 0.80 ± 0.03 0.60 ± 0.06 
 0.55    55 ± 2 0.82 ± 0.03 0.68 ± 0.06 
  0.60       55 ± 1 0.73 ± 0.02 0.55 ± 0.03 
Discussion 
The in vitro method for investigating distribution of drugs in blood commonly uses 
whole blood freshly prepared and pooled. Drug concentrations in blood and plasma 
are determined. Based on these data, further partition parameters, including CBC, FP, 
BPR, and BCPR, can be estimated, but they are partially dependent on the 
hematocrit. Therefore, it is important to know how the hematocrit affects these 
parameters, thereby providing useful information for comparing results. With this in 
mind, present experiments were performed over the entire physiological hematocrit 
range in blood pools of three different species (mouse, dog, and human). COM2 was 
used as test compound due to sufficient availability.  
The rank order of hematocrit influences was FP > BCPR > BPR > CB ≈ CP ≈ CBC 
with most pronounced changes for FP and none for CB/CP/CBC. Parameters 
calculated from concentrations measured in samples decreased constantly with 
increasing the hematocrit (0.40-0.60), which was most distinct for FP. But within a 
hematocrit variation of 0.05 none of the parameters was dependent on the 
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hematocrit. Consequently, blood partition data obtained from in vitro experiments 
with similar hematocrits are consistent and can be compared together. For data 
comparison across studies, hematocrit adjusting to values of previous studies is 
suggested taking into consideration a difference of ≤0.05 between the lowest and 
highest value. 
4.3 Major binding proteins of model compounds 
In vitro results  
Figure 4-2 illustrates the qualitative binding of model compounds to isolated 
proteins compared to the total fraction bound in plasma. The following ranking was 
obtained with regard to decreasing order of protein binding:  
COM1: albumin > α1-acid glycoprotein > γ-globulins ≈ lipoproteins; 
COM2: albumin > lipoproteins > γ-globulins >> α1-acid glycoprotein; 
COM3: α1-acid glycoprotein > albumin > γ-globulins >> lipoproteins; 
COM4: albumin > α1-acid glycoprotein >> γ-globulins ≈ lipoproteins; 
COM5: albumin ≈ α1-acid glycoprotein >> γ-globulins ≈ lipoproteins. 
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Figure 4-2 Qualitative differences in protein binding patterns of model compounds in vitro  
Total protein-bound fraction of compounds in human plasma compared to the qualitative extent of 
compound binding to various isolated human proteins (albumin, AGP, γ-globulins, and lipoproteins 
such as HDL, LDL, and VLDL). Each bar represents mean ± SD (n=3). 
Discussion 
In vitro experiments showed the binding of model compounds with different degrees 
to the three major drug-binding proteins in plasma (albumin, α1-acid glycoprotein, 
lipoproteins). A high binding to albumin (A) and α1-acid glycoprotein (AGP) was 
found for COM1 and COM4 (A>AGP), COM5 (A≈AGP), and COM3 (A<AGP). In 
contrast, COM2 was highly bound to albumin and lipoproteins. 
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4.4 The impact of Vitamin E TPGS on COM1 in rat 
In vitro results 
The equilibrium of COM1 between plasma and blood cells was reached within few 
minutes (<5 min, data not shown), and the fraction of COM1 distributed in plasma 
(~75%) was independent of initial blood concentrations of COM1 (0.06-6 ng/mL) and 
of excipients at 0.5% (Table 4-2). Enhancing the excipient concentration to 5% in 
blood resulted in decreased COM1 in blood cells, especially in the presence of TPGS 
(Table 4-2). In plasma, COM1 was highly protein bound with high contribution of 
albumin and α1-acid glycoprotein in binding (Figure 4-2), and a lower free fraction 
was found for COM1 in TPGS at 5% (Table 4-2). TPGS was taken for the in vivo 
study due to the most pronounced changes observed in the in vitro experiments. 
Table 4-2 Effect of excipients on blood distribution and protein binding of COM1 in vitro 
Partition parameters of [3H]COM1 at 0.06-6 ng/mL obtained at equilibrium after incubation with and 
without excipients in rat blood (pH 7.4, H 0.46 ± 0.03, n ≥3, mean ± SD). 
Excipient    FP BPR  BCPR fu ρ 
  (%) (%)     (%)   
None   72.8 ± 2.2 0.71 ± 0.02 0.41 ± 0.04 4.1 ± 0.2 9.9 ± 1 
HP-β-CyD 0.5 79.8 ± 1.7 0.65 ± 0.01 0.27 ± 0.02 nd nd 
 5 88.2 ± 2.4 0.63 ± 0.02 0.17 ± 0.04 nd nd 
Solutol 0.5 70.2 ± 2.4 0.73 ± 0.01 0.43 ± 0.01 nd nd 
 5 87.8 ± 2.3 0.64 ± 0.01 0.18 ± 0.02 nd nd 
TPGS 0.5 80.2 ± 2.4 0.64 ± 0.01 0.26 ± 0.01 3.9 ± 0.7 6.6 ± 0.3 
  5 95.6 ± 2.0 0.63 ± 0.01 0.08 ± 0.03 1.7 ± 0.3 5.3 ± 1.5 
In vivo results 
In contrast to the control group where a dose of 4 µg/kg was applied, COM1 was 
administered in the TPGS group at 2.7 µg/kg due to little compound availability. Data 
presented within this section are normalized to a dose of 1 µg/kg. 
Independent of the formulation, plasma levels declined very rapidly with an 
apparent half-life of 0.17 h, and COM1 was rapidly metabolized (<30% unchanged 
COM1 in plasma at 0.08 h post-dose). Metabolites were fast eliminated from body, 
indicated by a low recovery of administered COM1 shortly after dosing (<30% of 
administered dose recovered at 0.08 h post-dose). 
Upon intravenous administration of COM1 as a TPGS-containing solution, lower 
total plasma concentrations combined with an increase of COM1 unbound in plasma 
by 50% were found in contrast to the control group (Table 4-3, Figure 4-3). However, 
free drug concentrations in plasma did not differ between both groups, resulting in 
similar AUCs (Table 4-3). This is in line with identical tissue concentrations observed 
in both groups (data not shown) since only the unbound drug is supposed to pass 
across membranes. Furthermore, COM1 in TPGS led to a lower fraction of parent 
drug in plasma (funchanged, Table 4-3) and higher metabolite-related concentrations in 
plasma (2-fold increase, Figure 4-3), indicating alterations in the kinetic profile of 
metabolites. 
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Table 4-3 Comparative plasma kinetics of COM1 with and without TPGS 
Plasma concentrations and pharmacokinetic parameters of [3H]COM1 administered intravenously in 
formulations based on glucose 5% (control) or TPGS 20% to rats (LOQ=2 pg/mL, n=3, mean ± SD). 
Data are normalized to a dose of 1 µg/kg. AUC(u)0.08-0.5h relates to area under unbound drug plasma 
concentration-time curve. 
Time Control TPGS 
(h) COM1 in plasma (pg/mL) 
Percentage of 
control value 
0.08 184 ± 77 110 ± 6 60 
0.25 59 ± 13 39 ± 6 66 
0.5 32 ± 11 20 ± 6 62 
C0 (pg/mL) 215 132  
AUC0.08-0.5h (pg·mL-1·h) 32 20  
AUC(u)0.08-0.5h (pg·mL-1·h) 0.67 0.76  
t1/2 (h) 0.17 0.17  
funchanged (%) 18.7 5.5  
fu (%) 2.1 ± 0.1 3.8 ± 0.3 
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Figure 4-3 Influence of TPGS on the systemic exposure of COM1 and metabolites 
Plasma concentration-time profiles of parent drug and metabolite-related radioactivity of [3H]COM1 
after intravenous administration to rats. COM1 was injected in glucose 5% (closed symbols, black line) 
or TPGS 20% (open symbols, dashed line). Data shown are normalized to a dose of 1 µg/kg, and 
symbols represent single values and lines mean values (n=3). Values of metabolite-related 
radioactivity were obtained by subtracting concentrations of parent drug from concentrations of total 
radioactivity. 
Discussion 
Drug-excipient interaction studies showed no direct correlation between the in vitro 
results and the in vivo situation in rats. Upon intravenous administration of COM1 in 
TPGS, slightly lower plasma concentrations and binding to plasma proteins were 
observed in animals as compared to those received COM1 in a TPGS-free solution. 
In contrast to these in vivo findings, COM1 displayed in vitro no alterations in the 
presence of TPGS at 0.5%, whereas a higher TPGS concentration (5%) led to 
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enhanced distribution into plasma and a higher fraction bound in plasma. 
Furthermore, very rapid metabolism and elimination of COM1 under in vivo 
conditions contributed to a pharmacokinetic profile inappropriate for studying drug-
excipient interactions. 
4.5 The impact of Vitamin E TPGS on COM2 in mouse 
In vitro results 
To assess whether the ultracentrifugation time could be shortened for minimizing 
the degradation of COM2 in plasma (147), blank plasma samples were centrifuged, 
and time aliquots were analyzed for total protein concentrations in plasma and 
plasma water. After 4-h centrifugation, protein levels in the plasma water section 
were below 0.05 ng/mL corresponding to ~0.1% of total plasma proteins adequate to 
assure a sufficient separation of plasma water and proteins. Therefore, samples were 
collected after 4-h centrifugation for analysis. 
COM2 (0.01-100 ng/mL) distributed almost equally between whole blood and 
plasma (FP ~45%) and was very highly bound to plasma proteins (>98%, mainly to 
albumin and lipoproteins) (Figure 4-2). The plasma fraction (63%) was enhanced for 
COM2 in TPGS at the beginning (<1-h incubation) followed by equalization to 
excipient-free incubations (Table 4-4, Figure 4-4). The presence of TPGS reduced 
also the free fraction in plasma by 30% (Table 4-4). Finally, TPGS was selected for 
the in vivo study because of the most pronounced drug-excipient interactions 
detected in vitro. 
Table 4-4 Effect of excipients on blood distribution and protein binding of COM2 in vitro 
Partition parameters of [3H]COM2 at 0.1 ng/mL obtained at equilibrium after incubation with and 
without excipients (0.5%) in mouse blood (pH 7.3, H 0.45, n≥3, mean ± SD). 
Excipient  Time FP BPR BCPR fu ρ 
  (h) (%)     (%)   
None 0.08 40.6 ± 0.7 1.36 ± 0.02 1.79 ± 0.05 102 ± 3 
 1 44.8 ± 2.4 1.23 ± 0.07 1.51 ± 0.15 
1.76 ± 0.03 
86 ± 8 
CEL/EtOH, 65:35(v/v) 0.08 45.5 ± 1.4 1.21 ± 0.04 1.46 ± 0.09 nd 
 1 43.8 ± 0.3 1.25 ± 0.01 1.57 ± 0.02 nd nd 
HP-β-CyD 0.08 47.2 ± 1.4 1.17 ± 0.09 1.38 ± 0.19 nd 
 1 49.4 ± 1.6 1.11 ± 0.04 1.25 ± 0.08 nd nd 
Solutol 0.08 46.8 ± 1.1 1.18 ± 0.03 1.39 ± 0.06 nd 
 1 47.2 ± 1.6 1.17 ± 0.04 1.37 ± 0.09 nd nd 
PEG 200 0.08 42.5 ± 1.3 1.29 ± 0.04 1.65 ± 0.09 nd 
 1 41.8 ± 2.0 1.32 ± 0.06 1.71 ± 0.14 nd nd 
TPGS 0.08 62.9 ± 2.3 0.87 ± 0.03 0.72 ± 0.07 58 ± 7 
  1 53.3 ± 0.7 1.03 ± 0.01 1.07 ± 0.03 
1.22 ± 0.12 
88 ± 3 
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Figure 4-4 TPGS-mediated alteration of COM2 distribution in blood 
Blood-plasma (a), blood cell-plasma (b), and blood cell-unbound in plasma (c) concentration ratios of 
[3H]COM2 at 0.1 ng/mL in the presence (white bars) and absence (black bars) of TGPS (0.5%) after 
0.08-h and 1-h incubation in mouse blood (pH 7.3, H 0.45, n≥3, mean ± SD). 
In vivo results 
In a previous study (153), the disposition kinetics of COM2 was evaluated in mice 
after iv administration in a solution containing HP-β-CyD 10% (5 mL/kg). To enable a 
comparison of former data with those in the current investigation for internal 
purposes only, COM2 was injected at a volume of 5 mL/kg dissolved in plasma or 
TPGS 10%. The blood concentration of TPGS from this injection preparation was 
estimated as ~0.7% assuming a blood volume of 72 mL/kg. Thus, the amount of 
TPGS in blood was higher in vivo compared to the amount used in vitro (0.5%). 
The administration of COM2 as TPGS-containing solution at the same dosage 
caused approximately 2-fold higher plasma concentrations as compared to COM2 
formulated in plasma (control) (Table 4-5, Figure 4-5). These findings are in line with 
data obtained in blood distribution studies in vitro, where partitioning into blood cells 
was reduced in the presence of TPGS, resulting in a higher concentration in plasma 
at the same total blood concentration. Furthermore, in vivo a higher plasma exposure 
to metabolites and a slower elimination of metabolites from the systemic circulation 
were found for COM2 in TPGS, indicated by 4-fold increased AUC and t1/2 of 
metabolite-related radioactivity in plasma (Table 4-6). Determination of unbound 
COM2 in plasma could not be performed on samples from mice due to 
concentrations below LOQ (3 pg/mL). 
No differences in tissue concentrations were observed between both groups, 
although COM2 in TPGS resulted in a decrease of V0 (Table 4-5) and KP (Table 4-7), 
both suggesting altered tissue distribution and being in line with higher drug 
accumulation in the circulation. Because the free drug fraction in plasma generally 
reflects more accurately distribution processes due to the ability of unbound drugs to 
pass through membranes and then reach the target organ, the free drug fraction 
determined in vitro was considered. Calculated tissue-unbound in plasma 
concentration ratios, KP(u), were reduced in the TPGS group only within the first 
minutes after drug administration (Table 4-7). 
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Table 4-5 Comparative plasma kinetics of COM2 with and without TPGS 
Plasma concentrations (a) and pharmacokinetic parameters (b) of [3H]COM2 after iv dosing at 
400 ng/kg in formulations based on blank plasma (control) or TPGS to mice (LOQ=3 pg/mL, n=3, 
mean ± SD). *,** significantly different from the control at P<0.05 and 0.01, respectively. 
(a) 
Time COM2 in plasma (pg/mL) 
(h) Control TPGS 
Percentage of 
control value 
0.08 104 ± 11 247 ± 23** 238 
0.25 81 ± 12 159 ± 16** 196 
0.5 59 ± 2 124 ± 17* 210 
1 34 ± 7 80 ± 17* 235 
(b) 
Parameter Unit Formulation 
    Blank plasma TPGS 10% 
Body weight kg 0.028 0.027 
Dose ng 11.0 10.7 
C0 pg/mL 111 237 
t½ h 0.57 0.61 
V0 L/kg 3.6 1.7 
AUC0.08-1h pg·mL-1·h 56 121 
Dose/AUC0.08-1h mL/h 196 89 
funchanged % 54 35 
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Figure 4-5 Influence of TPGS on the systemic exposure of COM2 and metabolites 
Plasma concentration-time profiles of parent drug and metabolite-related radioactivity of [3H]COM2 
after intravenous administration to mice at 400 ng/kg formulated in blank plasma (closed symbols, 
black line) or as a solution containing TPGS 10% (open symbols, dashed line). Symbols represent 
single values and lines mean values (n=3). Values of metabolite-related radioactivity were obtained by 
subtracting concentrations of parent drug from concentrations of total radioactivity. 
  
32
Table 4-6 Comparative plasma kinetics of metabolites of COM2 with and without TPGS 
Plasma concentrations and pharmacokinetic parameters of metabolite-related radioactivity after iv 
administration of [3H]COM2 (400 ng/kg) in blank plasma (control) or TPGS 10% to mice 
(n=3, mean ± SD). Values of metabolite-related radioactivity were obtained by subtracting 
concentrations of parent drug from concentrations of total radioactivity. ** significantly different from 
the control at P<0.01. 
Time Control TPGS 
(h) Metabolites in plasma (pg-eq/mL) 
Percentage of 
control value 
0.08 75 ± 6 307 ± 28** 408 
0.25 67 ± 4 233 ± 9** 346 
0.5 56 ± 2 246 ± 30** 441 
1 29 ± 8 218 ± 31** 744 
AUC0.08-1h  (pg·mL-1·h) 49 222 453 
t1/2 (h) 0.6 2.4 395 
 
Table 4-7 Comparison of tissue distribution of COM2 with and without TPGS 
Tissue concentrations and tissue-plasma concentration ratios (KP) of [3H]COM2 administered 
intravenously at 400 ng/kg in blank plasma (control) or 10% TPGS solution to mice (n=3). KP(u) relates 
to the free compound  concentration in plasma based on the free fraction determined in vitro. Values 
represent mean ± SD. 
Time Tissue Concentration (pg/g) KP KP(u) 
(h) 
  Control TPGS Control TPGS Control TPGS 
0.08 Lung 1808 ± 263 1861 ± 64 17.3 ± 0.7 7.6 ± 0.5 981 ± 39 621 ± 42 
 Heart 750 ± 111 699 ± 33 7.2 ± 0.3 2.8 ± 0.1 407 ± 17 233 ± 11 
 Liver 2188 ± 355 2314 ± 56 20.9 ± 1.2 9.4 ± 0.9 1186 ± 69 773 ± 72 
 Kidney 1761 ± 390 1735 ± 84 16.7 ± 2.2 7.1 ± 0.7 951 ± 124 580 ± 59 
 Fat 232 ± 94 238 ± 83 2.2 ± 0.9 1 ± 0.3 127 ± 49 79 ± 25 
 Muscle 166 ± 40 190 ± 82 1.6 ± 0.6 0.8 ± 0.3 92 ± 32 62 ± 22 
 Brain 1095 ± 70 1038 ± 113 10.5 ± 0.6 4.2 ± 0.1 598 ± 35 345 ± 9 
0.25 Lung 1206 ± 258 1277 ± 213 15 ± 2.6 8 ± 0.5 850 ± 148 657 ± 43 
 Heart 464 ± 31 473 ± 19 5.8 ± 0.6 3 ± 0.2 330 ± 37 246 ± 20 
 Liver 1447 ± 203 1626 ± 122 18 ± 1.9 10.3 ± 1.3 1024 ± 109 846 ± 109 
 Kidney 1176 ± 93 1161 ± 83 14.7 ± 1.9 7.4 ± 1 837 ± 108 605 ± 86 
 Fat 650 ± 169 1109 ± 321 8.1 ± 1.9 7.1 ± 2.4 458 ± 108 581 ± 198 
 Muscle 215 ± 13 214 ± 28 2.7 ± 0.5 1.4 ± 0.1 155 ± 28 111 ± 12 
 Brain 1199 ± 143 1180 ± 81 15.2 ± 3.4 7.5 ± 1.2 863 ± 194 616 ± 100 
0.5 Lung 755 ± 76 923 ± 40 12.9 ± 1.5 7.5 ± 0.6 732 ± 83 615 ± 53 
 Heart 296 ± 34 354 ± 53 5 ± 0.6 2.9 ± 0.4 287 ± 34 234 ± 29 
 Liver 960 ± 91 1138 ± 58 16.3 ± 1.5 9.3 ± 1.2 929 ± 88 760 ± 100 
 Kidney 814 ± 102 987 ± 120 13.9 ± 1.9 8 ± 0.4 789 ± 110 654 ± 34 
 Fat 863 ± 227 1079 ± 444 14.7 ± 3.7 8.9 ± 5.1 834 ± 209 732 ± 416 
 Muscle 181 ± 12 170 ± 13 3.1 ± 0.2 1.4 ± 0.2 175 ± 11 113 ± 13 
 Brain 1086 ± 108 1215 ± 147 18 ± 1.8 9.8 ± 0.8 1050 ± 77 805 ± 69 
1 Lung 439 ± 60 688 ± 187 13.3 ± 3.2 8.6 ± 0.5 758 ± 179 702 ± 43 
 Heart 186 ± 28 220 ± 72 5.7 ± 1.5 2.7 ± 0.4 322 ± 87 222 ± 31 
 Liver 581 ± 43 867 ± 140 17.6 ± 2.3 11 ± 1.5 998 ± 132 903 ± 123 
 Kidney 481 ± 37 740 ± 89 14.5 ± 1.9 9.4 ± 0.9 825 ± 105 771 ± 78 
 Fat 551 ± 143 504 ± 260 17.3 ± 7.7 7.1 ± 5.4 984 ± 439 584 ± 442 
 Muscle 91 ± 12 119 ± 37 2.8 ± 0.8 1.5 ± 0.3 159 ± 43 121 ± 25 
 Brain 731 ± 88 1073 ± 161 22 ± 2.6 13.6 ± 1.1 1249 ± 147 1114 ± 93 
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Discussion 
Results signified the ability of the excipient TPGS to modify the blood distribution of 
COM2 in mouse under in vitro and in vivo conditions in a similar manner. Plasma 
concentrations of COM2 and metabolites were significantly increased, and the free 
fraction of drug in plasma (in vitro) decreased. Concentrations in tissues were 
independent of the formulation, whereas distribution ratios of drug in tissue to drug 
unbound in plasma were lower within the first minutes after dosing COM2 in TPGS. 
Overall, the altered pharmacokinetic profile of COM2 in plasma suggests drug 
inclusion in excipient-micelles and/or promoted protein binding by excipient in 
plasma. 
The altered disposition of COM2 and metabolites in plasma is likely caused by the 
ability of TPGS to form micelles (141). Drug trapping by micelles in blood can be 
responsible for increased total plasma concentrations and decreased unbound 
fraction in plasma, thereby influencing drug accumulation in plasma and blood cells 
(94). Changes in the free fraction could also be caused by altered protein binding. 
There are different suggested mechanisms by which formulation vehicles can 
influence the free fraction of compounds, such as vehicle-compound interactions 
(association and/or micellar encapsulation) and vehicle-protein interactions. The 
interaction either promotes or blocks the binding of the compound in plasma. Most 
likely, different interacting processes contribute to the effective free fraction (125). 
The alteration in tissue distribution at the beginning may be induced by changes of 
the free drug fraction in the presence of TPGS and exists only for few minutes 
probably due to the excipient degradation in blood. The phenomenon found after 
some minutes post-dose is reported in the literature for Paclitaxel formulated in 
Cremophor EL (94). The main characteristics are disproportionally increased plasma 
concentrations accompanied by unchanged tissue levels and tissue distribution 
processes. 
4.6 The impact of hydroxypropyl-β-cyclodextrin on COM3 in rat 
In vitro results 
COM3 was predominantly located in the cellular fraction (80%) and was moderately 
bound to plasma proteins with high binding to α1-glycoprotein and albumin in a 
concentration-independent manner (Table 4-8, Figure 4-2). The drug partitioning into 
blood cells and the fraction bound to proteins were markedly reduced in incubations 
containing HP-β-CyD, consequently lowering both the blood-plasma and 
blood cell-unbound in plasma concentration ratios (Table 4-8, Figure 4-6). Whereas 
HP-β-CyD decreased the protein binding suggesting more COM3 available for 
uptake into cells, higher plasma levels associated with reduced concentrations in 
cells were observed for COM3 in HP-β-CyD. In conclusion, HP-β-CyD was selected 
for the in vivo study because of the most pronounced drug-excipient interactions 
detected in vitro. 
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Figure 4-6 HP-β-CyD-mediated alteration of COM3 distribution in blood 
Blood-plasma (a), blood cell-plasma (b), and blood cell-unbound in plasma (c) concentration ratios of 
[3H]COM3 at 5 (white bars) and 500 ng/mL (black bars) in the presence and absence of HP-β-CyD 
(0.5%) after incubation in rat blood (pH 7.6, H 0.44, n≥3, mean ± SD). 
Table 4-8 Effect of excipients on blood distribution and protein binding of COM3 in vitro 
Partition parameters of [3H]COM3 obtained at equilibrium after incubation with and without excipients 
(0.5%) in rat blood (pH 7.6, H 0.44, n≥3, mean ± SD). 
Excipient COM3 FP BPR BCPR fu ρ 
  (ng/mL) (%)   (%)  
None 5 20.9 ± 1.5 2.6 ± 0.1 4.6 ± 0.2 12.1 ± 0.9 39.9 ± 3.9 
 500 19.5 ± 0.3 2.9 ± 0.0 5.3 ± 0.1 12.2 ± 0.2 43.1 ± 0.8 
5 19.4 ± 1.4 2.9 ± 0.2 5.6 ± 0.2 nd nd CEL/EtOH,     
65:35 (v/v) 500 17.5 ± 0.3 3.2 ± 0.1 6.0 ± 0.1 nd nd 
HP-β-CyD 5 38.5 ± 2.2 1.4 ± 0.1 2.1 ± 0.2 40.1 ± 1.8 5.1 ± 0.5 
 500 35.3 ± 0.4 1.6 ± 0.0 2.3 ± 0.0 39.6 ± 0.7 5.9 ± 0.1 
Solutol 5 17.4 ± 1.4 3.2 ± 0.3 6.1 ± 0.4 nd nd 
 500 16.1 ± 0.3 3.5 ± 0.1 6.7 ± 0.1 nd nd 
PEG 200 5 19.7 ± 2.0 2.9 ± 0.3 5.1 ± 0.6 nd nd 
 500 18.6 ± 0.5 3.0 ± 0.1 5.6 ± 0.2 nd nd 
5 22.7 ± 1.8 2.5 ± 0.2 4.4 ± 0.4 12.6 ± 0.1 34.6 ± 3.6 EtOH/PEG200/Glu, 
5:5:90 (v/v/v) 500 20.0 ± 0.4 2.8 ± 0.1 5.1 ± 0.1 11.8 ± 0.2 43.2 ± 1.0 
TPGS 5 24.9 ± 1.8 2.3 ± 0.2 4.0 ± 0.2 nd nd 
  500 23.7 ± 0.3 2.4 ± 0.0 4.1 ± 0.1 nd nd 
In vivo results 
Since COM3 dissolved in EtOH/PEG200/Glu (5:5:90, v/v/v) showed similar 
distribution kinetics in vitro as compared to glucose 5% without additives (Table 4-8), 
the control formulation consisted of EtOH/PEG200/Glu. This assured a sufficient 
solubility of COM3. 
Dosing COM3 in a HP-β-CyD-containing formulation resulted in decreased protein 
binding and blood cell partitioning as compared to the control group (Table 4-9). 
However, these changes were transient and most pronounced after 5 min 
post-dosing followed by a decline. At 60 min after drug administration, differences in 
blood pharmacokinetics could not be longer detected between both groups anymore 
(Table 4-9). In contrast to the in vitro findings, a lower plasma distribution was found 
at 5 min after applying COM3 in HP-β-CyD, resulting in slightly enhanced 
blood-plasma and blood cell-plasma concentration ratios (Table 4-9, Figure 4-7). 
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The bolus injection of COM3 in HP-β-CyD led to an earlier decrease of kidney and 
lung concentrations and to a later decrease of skin, liver, and fat concentrations, 
compared to tissue levels obtained after administration of COM3 alone (Table 4-11). 
The calculation of tissue-blood concentration ratios supported the lower distribution 
of COM3 formulated in HP-β-CyD (Table 4-11), especially at 1 h post-dose 
(Figure 4-8). 
As a result of the difference in plasma pharmacokinetic parameters (Table 4-10) 
and tissue levels between both groups, the renal elimination of COM3 was examined 
in addition. More COM3 appeared in the urine of rats from the HP-β-CyD containing 
formulation (Table 4-12, Figure 4-9), especially within the first 30 minutes after drug 
administration (36-fold higher amount of unchanged COM3 in urine compared to the 
control group). 
Table 4-9 Comparison of blood and plasma levels of COM3 with and without HP-β-CyD 
[3H]COM3 concentrations in the systemic circulation (a) and partition parameters derived from these 
concentrations (b) after iv administration to rats at 300 µg/kg formulated in HP-β-CyD or in a 
cyclodextrin-free solution (n=3, mean ± SD, LOQ=0.08 ng/mL, assuming a hematocrit of 0.46(145) for 
calculations). *,** significantly different from the control at P<0.05 and 0.01, respectively. 
(a) 
Formulation Time (h) Drug concentration (ng/mL) 
    Blood Plasma 
EtOH/PEG200/Glu, 5:5:90 0.08 43.1 ± 6.8 17.5 ± 2.4 
(control) 0.5 17.9 ± 4.0 6.1 ± 1.9 
 1 9.7 ± 0.9 4.1 ± 0.5 
HP-β-CyD 40% 0.08 32.7 ± 1.6 10.4 ± 1.1* 
 0.25 26.3 ± 2.2 8.4 ± 0.9 
 0.5 18.0 ± 0.8 5.9 ± 0.1 
  1 10.4 ± 0.6 3.5 ± 0.2 
 (b) 
Formulation Time (h) fu (%) FP (%) BPR BCPR ρ 
0.08  22.5 ± 1.5 2.5 ± 0.2 4.2 ± 0.4 55.9 ± 4.8 EtOH/PEG200/Glu, 
5:5:90 0.5 7.6 ± 0.8 18.7 ± 1.9 3.0 ± 0.3 5.4 ± 0.7 70.9 ± 8.9 
 (control) 1   23.3 ± 1.2 2.4 ± 0.1 4.0 ± 0.3 53.3 ± 3.7 
HP-β-CyD 40% 0.08 24.9 ± 1.2* 17.4 ± 1.1 3.2 ± 0.2** 5.8 ± 0.4 23.3 ± 1.7 
 0.25 17.7 ± 1.3 17.5 ± 0.6 3.1 ± 0.1 5.8 ± 0.2 32.5 ± 1.3 
 0.5 14.1 ± 0.6* 18.0 ± 0.7 3.1 ± 0.1 5.6 ± 0.3 39.7 ± 1.8 
  1 7.8 ± 0.5 18.8 ± 1.2 2.9 ± 0.2* 5.3 ± 0.4 68.1 ± 5.2 
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Table 4-10 Comparative pharmacokinetics of COM3 with and without HP-β-CyD 
Pharmacokinetic parameters of [3H]COM3 administered intravenously in EtOH/PEG 200/Glu (control 
group) or in HP-β-CyD 40% to rats (n=3). 
Parameter Unit Control group HP-β-CyD group 
    Blood Plasma Blood Plasma 
Body weight kg 0.233 0.221 
Dose µg 70 66 
C0 ng/mL 46 17 35 11 
V0 L/kg 6.6 17.4 8.5 27.1 
AUC0.08-1h ng·mL-1·h 19.7 7.5 17.7 5.8 
funchanged % 28 10 28 9 
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Figure 4-7 Influence of HP-β-CyD on the systemic exposure of COM3 
Blood and plasma concentration-time profiles of [3H]COM3 after intravenous administration to rats at 
300 µg/mL formulated in EtOH/PEG 200/Glu (open symbols, black line) and as a solution containing 
HP-β-CyD (closed symbols, dotted line). Symbols represent single values and lines mean 
values (n=3). 
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Figure 4-8 Influence of HP-β-CyD on tissue distribution of COM3 
Tissue to blood concentration ratio (KP) at 1 h after an iv injection of COM3 in EtOH/PEG 200/Glu 
(white bars) or in HP-β-CyD (black bars) in rats (dose: 300 µg/kg, n=3, mean ± SD). * significantly 
different from EtOH/PEG 200/Glu at P<0.05. 
Table 4-11 Comparison of tissue distribution of COM3 with and without HP-β-CyD 
Tissue concentrations and tissue-blood concentration ratios (KP) of [3H]COM3 after bolus injection to 
rats at 300 µg/kg in EtOH/PEG 200/Glu (control) or HP-β-CyD (n=3, mean ± SD). * significantly 
different from the control at P<0.05. 
Time  Tissue Concentration (ng/mL)   KP 
(h)   Control HP-β-CyD 
Percentage of 
control value 
  Control HP-β-CyD 
0.08 Liver 1412 ± 225 1058 ± 211 75  32.8 ± 0.1 32.6 ± 7.5 
 Kidney 1809 ± 191 1406 ± 72* 78  42.4 ± 5.0 43.1 ± 2.4 
 Fat 128 ± 29 85 ± 18 67  3.1 ± 1.1 2.6 ± 0.6 
 Heart 597 ± 108 563 ± 55 94  13.9 ± 1.1 17.2 ± 1.3* 
 Lung 6179 ± 809 4595 ± 192* 74  144.1 ± 11.0 140.7 ± 6 
 Muscle 123 ± 25 142 ± 12 115  3.0 ± 1.1 4.4 ± 0.3 
 Skin 144 ± 62 74 ± 15 51  3.6 ± 2.0 2.2 ± 0.3 
  Brain 1164 ± 189 951 ± 41 82   27.1 ± 1.9 29.1 ± 2.1 
0.5 Liver 588 ± 149 617 ± 60 105   32.9 ± 5.3 34.5 ± 4.2 
 Kidney 587 ± 163 479 ± 55 82  32.7 ± 5.1 26.7 ± 2.9 
 Fat 57 ± 10 46 ± 6 81  3.2 ± 0.2 2.6 ± 0.4 
 Heart 178 ± 46 187 ± 23 105  9.9 ± 1.0 10.4 ± 0.8 
 Lung 2003 ± 599 2376 ± 129 119  110.8 ± 15.6 132.4 ± 7.6 
 Muscle 155 ± 63 130 ± 12 84  8.4 ± 1.6 7.2 ± 0.5 
 Skin 94 ± 11 40 ± 9* 42  5.4 ± 0.6 2.2 ± 0.6* 
  Brain 905 ± 100 766 ± 49 85   51.5 ± 6.0 42.8 ± 4.4 
1 Liver 394 ± 29 340 ± 6 86   40.7 ± 1.2 32.8 ± 1.9* 
 Kidney 357 ± 44 293 ± 39 82  36.6 ± 1.2 28.3 ± 4.7 
 Fat 31 ± 1 22 ± 5 72  3.2 ± 0.4 2.1 ± 0.4* 
 Heart 111 ± 13 99 ± 6 89  11.4 ± 0.4 9.5 ± 0.1* 
 Lung 1197 ± 128 1053 ± 178 88  124.7 ± 24.6 101.1 ± 12.8 
 Muscle 99 ± 9 85 ± 23 86  10.2 ± 0.2 8.1 ± 1.9 
 Skin 68 ± 16 25 ± 3* 37  6.9 ± 1.1 2.5 ± 0.2* 
  Brain 653 ± 35 599 ± 10 92   67.4 ± 2.7 57.8 ± 2.2* 
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Table 4-12 Comparison of COM3 excretion in urine with and without HP-β-CyD 
[14C]COM3 (a) and its cumulative amount (b) appeared in the urine of rats following iv dosing at 
370 µg/kg in EtOH/PEG 200/Glu (control) or HP-β-CyD 40% (mean ± SD, n=2: control, 
n=3: HP-β-CyD). *,** significantly different from the control at P<0.05 and 0.01, respectively. 
(a) 
Time (h) COM3 in urine (ng) funchanged (%) 
  Control HP-β-CyD Control HP-β-CyD 
0.5 123 ± 10 4440 ± 594** 2.5 ± 0.2 44.8 ± 8.2* 
1 240 ± 129 762 ± 191* 3.4 ± 0.8 13 ± 4.1 
1.5 85 ± 19 325 ± 150 2.5 ± 0.8 7.3 ± 2.8 
2 43 ± 11 174 ± 89 2 ± 0.8 4.6 ± 2.1 
(b) 
Time Cumulative amount of COM3 in urine 
(h) ng %dose 
  Control HP-β-CyD Control HP-β-CyD 
0.5 123 ± 10 4440 ± 594** 0.13 ± 0.01 4.6 ± 0.9** 
1 363 ± 139 5202 ± 693** 0.39 ± 0.14 5.4 ± 1.1** 
1.5 449 ± 159 5527 ± 799** 0.48 ± 0.16 5.7 ± 1.2** 
2 491 ± 169 5702 ± 857** 0.53 ± 0.17 5.9 ± 1.2** 
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Figure 4-9 Effect of HP-β-CyD on the renal elimination of COM3 
Cumulative amount of [14C]COM3 appeared in urine after iv administration of 370 µg/kg either in  
EtOH/PEG 200/Glu (white bars) or as a solution in HP-β-CyD (black bars). Data are expressed as 
mean ± SD (n=2: EtOH/PEG 200/Glu, n=3: HP-β-CyD). ** significantly different from the 
EtOH/PEG 200/Glu at P<0.01. 
Discussion 
In vitro and in vivo experiments demonstrated a strong influence of the excipient 
HP-β-CyD on the disposition kinetics of COM3 in rats. There was a significant 
decrease in the plasma protein binding and in plasma and tissue concentrations of 
COM3 formulated in HP-β-CyD. Changes in the systemic circulation were transient 
(≤0.5 h post-dose) and most distinct shortly after dosing. Alterations in tissue 
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concentrations and tissue-blood distribution ratios were tissue dependent and most 
pronounced for skin. The amount of unchanged COM3 eliminated in the urine was 
significantly increased following drug administration in HP-β-CyD. This alteration in 
the pharmacokinetic behavior of COM3 is most likely due to the elimination of COM3 
included in cyclodextrin complexes. 
It is known (142) that HP-β-CyD forms drug/cyclodextrin complexes in biological 
fluids, is unable to cross biological membranes, and is rapidly eliminated renally. 
Even though the release of drugs from drug/cyclodextrin complexes is expected to be 
fast (within seconds) (112) drug pharmacokinetics can be modified in the presence of 
cyclodextrins (143). Given that COM3 is included in complexes in the systemic 
circulation, less COM3 is available for distribution, which could have led to the lower 
protein binding and cell/tissue partitioning of COM3 formulated in HP-β-CyD, 
compared to the cyclodextrin-free solution of COM3. Lower ρ-values of COM3 in 
HP-β-CyD support the possible existence of long-lasting complexes in vivo and 
indicate that unbound plasma concentrations obtained from ultrafiltration (30000 MW 
cut-off) are probably the sum of free and cyclodextrin-associated drug (MWHP-β-CyD 
~1500). Furthermore, blood partition parameters altered till 30 min post-dose indicate 
a slow dissociation of COM3 from complexes. After total drug release, COM3 
formulated in HP-β-CyD seemed to assimilate the pharmacokinetic behavior in blood 
obtained in the control group (60 min post-dose). 
The marked increase of unchanged COM3 in the urine occurred mainly in the first 
30 min following drug administration in HP-β-CyD which is consistent with the 
decreased plasma levels right after dosing in the HP-β-CyD group. Similar 
observations are reported for carbamazepine and dexamethasone where the renal 
excretion of unchanged drug applied intravenously in HP-β-CyD was increased most 
likely due to the renal clearance of the formulation vehicle (112). The faster 
elimination of COM3 associated to HP-β-CyD in contrast to COM3 alone might have 
attributed to less COM3 available for tissue distribution even after completed drug 
release from the vehicle, being in line with decreased tissue levels and KP values at 
60 min post-dose. 
4.7 The impact of Cremophor EL on COM4 in rat 
In vitro results 
In excipient-free incubations, COM4 was highly bound to plasma proteins 
(>97% bound, predominantly to albumin) and penetrated hardly into blood cells 
(>95% located in plasma) (Tables 4-13 and 4-14, Figure 4-2). The free fraction in 
plasma and the partitioning into blood cells of COM4 were enhanced in the presence 
of CEL, HP-β-CyD, and Solutol. The protein binding decreased in an excipient 
concentration-dependent manner (Table 4-13, Figure 4-10). At excipient 
concentrations below 0.1%, the protein binding was not altered. At and above 
excipient concentrations of 0.1%, the free fraction was markedly elevated with a 
maximal effect at 1% for all three formulations. The addition of these excipients to 
incubations resulted to higher blood-plasma and blood cell-plasma concentration 
ratios, both indicating increased uptake of COM4 into blood cells (Table 4-14). CEL 
was selected for the in vivo study because of the most pronounced drug-excipient 
interactions detected in vitro. 
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Table 4-13 Effect of excipients on the in vitro protein binding of COM4 
Protein binding of [14C]COM4 at 100 ng/mL in the presence and absence of excipients in rat plasma 
using the ultrafiltration technique (pH 7.4, n=3, mean ± SD). 
Excipient   fu  
  (%) (%)  
Percentage of 
control value 
None   2.4 ± 0.2   
CEL 0.01 2.3 ± 0.1 96 
 0.1 3.1 ± 0.1 131 
 0.5 11.1 ± 0.3 464 
 1 26.0 ± 0.3 1089 
HP-β-CyD 0.01 2.6 ± 0.2 109 
 0.1 4.3 ± 0.2 179 
 0.5 9.8 ± 0.1 412 
 1 14.1 ± 1.1 592 
Solutol 0.01 2.3 ± 0.2 97 
 0.1 3.2 ± 0.2 134 
 0.5 9.7 ± 0.2 407 
 1 15.2 ± 0.3 638 
PEG 200 0.5 2.4 ± 0.1 99 
TPGS 0.5 2 ± 0.1 85 
Table 4-14 Effect of excipients on the in vitro partition parameters of COM4 in blood 
Plasma fraction (FP) and distribution ratios (BPR, BCPR, ρ) of [14C]COM4 at 100 ng/mL in rat blood 
obtained at equilibrium after incubations with and without excipients at 0.5 and 1% (pH 7.5, H 0.44, 
37°C, n≥3, mean ± SD). 
Excipient   FP  BPR  BCPR ρ 
  (%) (%)       
None   95.9 ± 2.0 0.58 ± 0.01 0.05 ± 0.03 2.1 ± 0.6 
CEL 0.5 73.9 ± 1.6 0.75 ± 0.02 0.43 ± 0.06 3.9 + 0.5 
 1 65.6 ± 1.7 0.85 ± 0.02 0.67 ± 0.05 2.6 + 0.2 
HP-β-CyD 0.5 90.0 ± 1.3 0.62 ± 0.01 0.14 ± 0.02 1.5 ± 0.2 
 1 81.9 ± 1.4 0.68 ± 0.01 0.28 ± 0.03 2.0 ± 0.2 
Solutol 0.5 78.6 ± 1.5 0.71 ± 0.01 0.35 ± 0.03 3.6 ± 0.3 
  1 74.9 ± 1.4 0.75 ± 0.01 0.43 ± 0.03 2.8 ± 0.3 
 
In vivo results 
Dosing COM4 in a CEL-containing formulation resulted in a decrease of the protein 
binding as compared to the control group (Table 4-15, Figure 4-10). This effect was 
time-dependent and most pronounced at 5 min after drug administration followed by 
a decline. The increased fraction of COM4 unbound in plasma did not affect the drug 
levels in the systemic circulation, resulting in similar pharmacokinetic parameters in 
both groups (Table 4-15). Identical tissue concentrations were observed 
independently of the formulation (Table 4-16). 
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Figure 4-10 Excipient-mediated alterations of COM4 protein binding in plasma 
Left: Unbound fraction of [14C]COM4 (100 ng/mL) incubated with different excipient concentrations in 
rat plasma (mean ± SD, n=3). Right: Unbound fraction of compound-related radioactivity in plasma 
after intravenous administration of [14C]COM4 at 400 µg/kg formulated in buffer (control group: closed 
symbols) or in CEL (open symbols). Symbols represent mean ± SD (n=3). 
Table 4-15 Comparative blood and plasma kinetics of COM4 with and without CEL 
Compound-related radioactivity concentrations in the systemic circulation (a) and pharmacokinetic 
parameters (b) after iv administration of [14C]COM4 at 400 µg/kg formulated in buffer or in CEL to rats 
(n=3, mean ± SD, LOQ=4.3 ng-eq/mL, assuming a hematocrit of 0.46(145) for calculations). 
* significantly different from the control at P<0.05. 
(a) 
Formulation  Time  (h) Concentration (ng-eq/mL) 
    Blood Plasma 
Unbound in 
plasma (%) 
0.08 1555 ± 299 2483 ± 382 
0.25 1192 ± 119 2073 ± 238 
0.5 1377 ± 67 2388 ± 153 
Phosphate buffered 
saline (control) 
1 1248 ± 68 2105 ± 172 
3.8 + 1.5 
Cremophor EL 17% 0.08 1471 ± 115 2426 ± 186 16.9 ± 3.4* 
 0.25 1316 ± 119 2180 ± 237 7.7 ± 2.4 
 0.5 1216 ± 155 2084 ± 237 7.4 ± 2.7 
  1 1315 ± 337 2210 ± 607 7.4 ± 2.8 
(b) 
Parameter Unit Control group Cremophor group 
    Blood Plasma Blood Plasma 
Body weight kg 0.201 0.199 
Dose µg 81 80 
C0 ng/mL 1427 2373 1385 2296 
V0 L/kg 0.28 0.17 0.29 0.17 
AUC0.08-1h ng·mL-1·h 1211 2068 1186 1998 
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Table 4-16 Comparison of tissue distribution of COM4 with and without CEL 
Tissue concentrations and tissue-blood concentration ratios of radioactivity of [14C]COM4 after bolus 
injection to rats at 400 µg/kg formulated either in buffer (control group) or in CEL (n=3, mean ± SD). 
Time Tissue Drug concentration (ng-eq/g)   Tissue-blood distribution ratio 
    Control group Cremophor group   Control group Cremophor group 
0.08 h Lung 737 + 78 768 + 17   0.48 + 0.04 0.52 + 0.03 
 Muscle 222 + 6 243 + 12  0.15 + 0.02 0.17 + 0.02 
 Skin 276 + 63 254 + 46  0.19 + 0.08 0.17 + 0.02 
0.25 h Lung 654 + 44 710 + 51  0.55 + 0.02 0.54 + 0.01 
 Muscle 209 + 5 211 + 6  0.18 + 0.02 0.16 + 0.02 
 Skin 363 + 70 395 + 41  0.30 + 0.04 0.30 + 0.04 
0.5 h Lung 695 + 46 676 + 40  0.50 + 0.01 0.56 + 0.04 
 Muscle 202 + 4 204 + 1  0.15 + 0 0.17 + 0.02 
 Skin 408 + 39 372 + 25  0.30 + 0.04 0.31 + 0.04 
1 h Lung 628 + 19 629 + 78  0.50 + 0.01 0.59 + 0.13 
 Muscle 212 + 10 196 + 13  0.17 + 0.01 0.19 + 0.08 
  Skin 409 + 24 391 + 45   0.33 + 0.01 0.37 + 0.09 
Discussion 
CEL lowered the binding of COM4 to plasma proteins in vitro, and the higher free 
drug fraction was associated with enhanced partitioning into blood cells as compared 
to the excipient-free incubations. Similar increases of unbound drug levels in plasma 
were observed after bolus injection of COM4 in CEL. In contrast to the in vitro 
findings, CEL induced no changes in the in vivo blood/plasma distribution of COM4, 
and no alterations in the tissue distribution were detected as well.  
Even though the plasma protein binding of COM4 is influenced by CEL in an 
analogous manner under in vitro and in vivo conditions, a direct translation of the 
altered protein binding into blood and plasma concentrations is lacking in vivo. 
Different to the in vitro investigations, the in vivo situation involves not only 
distribution but also elimination processes which can initiate shifts in the systemic 
drug exposure. Besides this, the effective excipient concentration achieved in vivo in 
the circulation is usually unknown and can quite differ from concentrations applied 
in vitro. Although excipient concentrations can be theoretically estimated using blood 
volume, dose, and application volume, values are fairly arbitrary because excipient 
levels can decline fast in the body due to dilution (144) and degradation (126) within 
the blood compartment. 
4.8 The impact of Solutol HS 15 on COM5 in rat 
In vitro results 
The distribution of COM5 between whole blood and plasma was slightly 
concentration-dependent in rat regardless of incubations with or without excipients 
(Table 4-17), and the equilibrium conditions were rapidly reached for all solutions 
(<5 min) except for CEL (equilibrium after 1-h incubation, data not shown). The 
binding of COM5 to plasma proteins was moderate (<90%) with a high binding to 
albumin and α1-acid glycoprotein (Figure 4-2), and the bound fraction was reduced 
by the addition of CEL and Solutol. Furthermore, both excipients caused alterations 
in the blood-plasma and blood cell-plasma concentration ratios, characterized by 
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enhanced drug partitioning into blood cells (Table 4-17, Figure 4-11). The higher cell 
uptake is consistent with decreased drug binding to plasma proteins in the presence 
of CEL and Solutol. These effects were more prominent for COM5 with Solutol than 
with CEL. Thus, Solutol was selected for the in vivo study. 
Table 4-17 Effect of excipients on blood distribution and protein binding of COM5 in vitro 
Partition parameters of [14C]COM5 obtained at equilibrium after incubation with and without excipients 
(0.5%) in rat blood (pH 7.5, H 0.45, n≥3, mean ± SD). 
Excipient COM5 FP BPR BCPR fu ρ 
 (ng/mL) (%)   (%)  
None 10 85.7 ± 4.0 0.64 ± 0.03 0.21 ± 0.07 16.2 ± 1.1 1.4 ± 0.3 
 300 76.8 ± 1.6 0.72 ± 0.02 0.37 ± 0.03 11.9 ± 0.2 3.1 ± 0.2 
Ethanol  10 81.2 ± 0.1 0.66 ± 0.05 0.23 ± 0.11 11.4 ± 0.4 2.2 ± 0.7 
 300 77.9 ± 0.9 0.72 ± 0.01 0.36 ± 0.02 11.6 ± 0.2 3.0 ± 0.2 
10 66.0 ± 2.2 0.83 ± 0.03 0.63 ± 0.06 22.7 ± 1.8 2.8 ± 0.3 CEL/EtOH,  
65:35 (v/v) 300 57.7 ± 1.2 0.95 ± 0.02 0.90 ± 0.04 23.7 ± 0.4 3.8 ± 0.2 
HP-β-CyD 10 80.3 ± 2.7 0.69 ± 0.02 0.30 ± 0.05 nd nd 
 300 75.4 ± 1.8 0.73 ± 0.02 0.40 ± 0.04 nd nd 
Solutol 10 55.0 ± 0.5 0.97 ± 0.06 1.00 ± 0.02 28.1 ± 1.0 3.3 ± 0.5 
 300 48.7 ± 0.9 1.13 ± 0.02 1.29 ± 0.04 27.7 ± 0.4 4.3 ± 0.4 
PEG 200 10 76.9 ± 2.3 0.72 ± 0.02 0.37 ± 0.05 nd nd 
 300 73.6 ± 1.3 0.75 ± 0.01 0.44 ± 0.03 nd nd 
TPGS 10 83.2 ± 1.3 0.63 ± 0.05 0.18 ± 0.12 nd nd 
 300 78.5 ± 1.8 0.70 ± 0.02 0.33 ± 0.04 nd nd 
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Figure 4-11 Excipient-mediated alterations of COM5 distribution in blood by CEL and Solutol 
Blood-plasma (a), blood cell-plasma (b), and blood cell-unbound in plasma (c) concentration ratios of 
[14C]COM5 (10-300 ng/mL) without excipients (black bars) and in the presence of Cremophor EL 
(white bars) and Solutol HS 15 (hatched bars) at 0.5% in rat blood (pH 7.5, H 0.45, n≥3, mean ± SD). 
In vivo results 
In vitro studies demonstrated that the addition of ethanol to incubations had no 
impact on the blood partition of COM5 (Table 4-17). Therefore, COM5 was dissolved 
in ethanol 10% for the administration in the control group, thereby assuring sufficient 
solubility of the compound 
Within the first 15 min post-dose, higher blood concentrations accompanied by 
similar plasma concentrations were observed for COM5 in Solutol compared to 
concentrations for COM5 in ethanol 10% (control group), thereby increasing 
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concentration ratios of blood-plasma and blood cell-plasma in the Solutol group 
(Table 4-18). Subsequently, similar ratios were obtained in both groups with a 
concomitant slower decline of circulation concentrations in animals treated with 
Solutol. These changes in the Solutol group are in line with a reduced rate constant 
that resulted in a 2-fold higher half-life compared to that in the control group 
(Table 4-19). At 1 h post-dose, concentrations of COM5 in the systemic circulation 
were 300% higher than those obtained after dosing the compound in the control 
formulation (Table 4-18, Figure 4-12). The dose/AUC ratio was also decreased for 
COM5 in Solutol (Table 4-19). In agreement with the in vitro findings, COM5 
formulated in Solutol led to a permanent lower protein binding up to 1 h post-dose in 
addition to enhanced uptake into blood cells right after dosing (higher blood-plasma 
concentration ratio) (Table 4-18). 
Table 4-18 Comparison of blood and plasma levels of COM5 with and without Solutol 
Concentrations of compound-related radioactivity in the systemic circulation (a) and partition 
parameters (b) derived from these concentrations after iv administration of [14C]COM5 at 1 mg/kg 
formulated in Solutol or in a Solutol-free solution (control group) to rats (n=3, mean ± SD, 
LOQ=8 ng-eq/mL, assuming a hematocrit of 0.46(145) for calculations). *,** significantly different from 
the control group at P<0.05 and 0.01, respectively. 
(a) 
 Time (h) Drug concentration (ng-eq/mL) 
    Control group Solutol group 
Percentage of 
control value 
Blood 0.08 1308 ± 178 1853 ± 155* 142 
 0.25 895 ± 195 1243 ± 250 139 
 0.5 615 ± 193 976 ± 115 159 
  1 194 ± 24 585 ± 113* 301 
Plasma 0.08 2592 ± 558 2720 ± 266 105 
 0.25 1584 ± 168 1895 ± 337 120 
 0.5 1014 ± 385 1526 ± 112 150 
  1 311 ± 47 900 ± 165* 289 
(b) 
Formulation Time (h) fu (%) FP (%) BPR BCPR ρ 
Control 0.08 106.2 ± 9.3 0.51 ± 0.04 -0.06 ± 0.1 -0.7 ± 1.1 
(ethanol 10%) 0.25 97.5 ± 14.8 0.56 ± 0.08 0.05 ± 0.17 1.9 ± 0.5 
 0.5 87.6 ± 12.5 0.62 ± 0.09 0.18 ± 0.19 4.2 ± 2.2 
  1 
8.4 ± 1.4 
 
86.2 ± 2.5 0.63 ± 0.02 0.19 ± 0.04 1.9 ± 0.4 
Solutol 17% 0.08 79.2 ± 1.8 0.68 ± 0.02** 0.31 ± 0.03 2.2 ± 0.2 
 0.25 82.5 ± 1.8 0.65 ± 0.01 0.25 ± 0.03 1.9 ± 0.2 
 0.5 84.7 ± 5.1 0.64 ± 0.04 0.21 ± 0.08 1.4 ± 0.5 
  1 
15.0 ± 2.3** 
83.2 ± 1.2 0.65 ± 0.01 0.24 ± 0.02 1.2 ± 0.1 
 
Independent of the formulation, brain levels ranged in concentrations corresponding 
to the vascular contamination, indicating no significant penetration of COM5 into 
brain (Table 4-20). A later increase in muscle and skin concentrations was detected 
for COM5 administered in Solutol (Table 4-20). The muscle concentration-time profile 
showed an analogous pattern to that in the systemic circulation with a longer 
persistence going along with higher concentrations at later post-dose times in the 
Solutol group (Table 4-21, Figure 4-12). However, similar muscle-plasma 
concentration ratios between both groups pointed that Solutol did not affect the 
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muscle distribution pattern. In contrast, the higher skin concentrations of COM5 
formulated in Solutol were associated with altered KP values (0.25 and 1 h post-dose) 
and same half-life compared to the control group (Tables 4-20 and 4-21). 
Table 4-19 Comparative pharmacokinetics of COM5 with and without Solutol 
Pharmacokinetic parameters of compound-related radioactivity after intravenous administration of 
[14C]COM5 in ethanol 10% (control group) or in Solutol 17% to rats (n=3).  
Parameter Unit Control group Solutol group 
    Blood Plasma Blood Plasma 
Body weight kg 0.214 0.212 
Dose µg 214 212 
C0 ng/mL 1562 2998 1840 2749 
V0 L/kg 0.64 0.33 0.54 0.36 
AUC0.08-1h ng·mL-1·h 578 1011 931 1426 
t1/2 h 0.33 0.32 0.69 0.69 
Dose/AUC0.08-1h mL/h 369 211 228 149 
 
Table 4-20 Comparison of tissue distribution of COM5 with and without Solutol 
Tissue concentrations and tissue-plasma concentration ratios of radioactivity of [14C]COM5 after bolus 
injection at 1 mg/kg to rats in ethanol 10% (control) or Solutol 17% (n=3, mean ± SD). 
Time Tissue Concentration (ng/g) 
  
Tissue-plasma ratio 
    Control Solutol 
Percentage of 
control value 
  Control Solutol 
0.08 h Muscle 400 + 53 476 + 69 119   0.16 ± 0.02 0.18 ± 0.04 
 Skin 248 + 26 240 + 48 97  0.10 ± 0.03 0.09 ± 0.03 
 Brain 27 + 3 40 + 2 150  0.01 ± 0 0.01 ± 0 
0.25 h Muscle 311 + 43 424 + 21* 137  0.20 ± 0.03 0.23 ± 0.04 
 Skin 243 + 15 413 + 62* 170  0.15 ± 0.01 0.22 ± 0.02* 
 Brain 16 + 2 26 + 4 161  0.01 ± 0 0.01 ± 0 
0.5 h Muscle 228 + 25 333 + 15* 146  0.25 ± 0.09 0.22 ± 0.01 
 Skin 235 + 33 384 + 11* 163  0.25 ± 0.08 0.25 ± 0.01 
 Brain 10 + 2 18 + 3 188  0.01 ± 0 0.01 ± 0 
1 h Muscle 57 + 2 174 + 30* 307  0.19 ± 0.03 0.19 ± 0 
 Skin 152 + 11 246 + 46 162  0.50 ± 0.11 0.28 ± 0.04 
  Brain —a 11 + 1 nd   0.01 ± 0 0.01 ± 0 
a: below LOQ, *:significantly different from the control at P<0.05 
 
Table 4-21 Comparison of muscle and skin kinetics of COM5 with and without Solutol  
Pharmacokinetic parameters of compound-related radioactivity in tissues after intravenous 
administration of [14C]COM5 at 1 mg/kg formulated in ethanol 10% (control group) or Solutol 17% to 
rats (n=3).  
Parameter Unit Muscle Skin 
    Control group Solutol group Control group Solutol group 
AUC0.08-1h ng·mL-1·h 199 298 198 313 
C0 ng/g 533 548 nd nd 
t1/2 h 0.30 0.58 1.04 0.97 
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Figure 4-12 Influence of Solutol on plasma, muscle, and skin profiles of COM5 
Concentration-time courses of compound-related radioactivity in plasma, muscle, and skin after 
intravenous administration of [14C]COM5 at 1 mg/kg formulated in ethanol 10% (closed symbols, black 
line) and as a solution containing Solutol 17% (open symbols, dotted line). Symbols represent single 
values and lines mean values (n=3). 
Discussion 
In vitro and in vivo experiments showed that Solutol significantly modulated the 
disposition profile of COM5 in rats by drug-excipient interactions in blood. COM5 
formulated in Solutol decreased both the drug distribution into plasma (transient 
in vivo) and the binding to plasma proteins (prolonged in vivo). Furthermore, animals 
treated with Solutol showed a later concentration increase in the circulation and 
tissues (muscle, skin) (≥0.25 h post-dose). 
Altered drug levels were related to prolonged half-lives in the circulation and 
muscle. The longer blood persistence is consistent with the reduced clearance 
(dose/AUC) which presumes a lower elimination of COM5 in the presence of Solutol. 
In contrast to the muscle concentration-time profile similar to that in the circulation, 
the skin profile exhibited no changes in the half-life, potentially due to a lower 
vascularization in skin compared to that in muscle. However, the skin-plasma 
concentration ratio was affected by the Solutol formulation, whereas no changes in 
KP values were observed for muscle. This altered pharmacokinetic profile might 
relate to a lower clearance of COM5 in the presence of Solutol. 
Previous investigations in mice revealed an interaction between Solutol and a 
co-administered ketochlorine photosensitizer (C8KC) in plasma (127). Protein 
binding experiments indicated the formation of either a binary drug-excipient complex 
or a ternary complex, involving drug, excipient, and plasma components. This effect 
was correlated to similar half-lives of Solutol and C8KC in plasma, suggesting the 
persistence of C8KC in the circulation associated with that of the excipient. Likewise, 
half-lives in the same range were also observed for C8KC and the excipient 
Cremophor EL, going along with prolonged C8KC persistence in plasma and tissues 
in mice (85). 
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5 General discussion and conclusions  
In vitro and in vivo experiments were carried out to investigate the potential of five 
excipients commonly used in formulations to modify the pharmacokinetics of 
co-administered model compounds at concentrations ranging from sub-therapeutic to 
pharmacological levels. Conducted studies focused mainly on the impact of 
excipients in the blood compartment, since such data have rarely been published up 
to now, especially for intravenously low dosed compounds including highly active 
drug substances, biomarkers, PET ligands, and microdoses. 
PEG 200, CEL, HP-β-CyD, and Solutol were chosen as excipients because of their 
use in intravenous formulations and their high solubilizing ability related to different 
molecular structures and solubilization principles by either a direct solvent effect or 
by formation of micelles or complexes. TPGS, known in oral formulations, completed 
the set of selected excipients and is an interesting functional excipient in terms of its 
chemical properties (benzyl ring) and ability to alter metabolism and/or transporter 
activities, thereby potentially influencing cellular distribution. 
Five drug candidates in development at Novartis were selected as model 
compounds, exhibiting different physicochemical and pharmacokinetic properties 
(Table 5-1). The two PET ligands COM1 (base) and COM2 are lipophilic and poorly 
water-soluble. COM3 is characterized by its predominant location in the cellular 
fraction in blood, whereas COM4 hardly penetrates into blood cells. COM2 distributes 
equally between plasma and whole blood. COM5 is a molecule with a high polar 
surface area and a low volume of distribution similar to that of COM4. Moreover, 
COM2, COM1, and COM4 are very highly protein bound (>95%), and COM3 and 
COM5 are moderately protein bound (<90%). In addition, binding studies using 
isolated plasma proteins showed that model compounds bind with different affinity to 
the three major drug-binding proteins in plasma (albumin, α1-acid glycoprotein, and 
lipoproteins). 
Model compounds were used in low doses to achieve blood concentrations of 
<5 ng/mL for COM1 and COM2 and low-therapeutic levels for COM3 (5-50 ng/mL). 
Due to the very low volume of distribution, COM4 and COM5 were investigated at 
normal pharmacological concentrations (>50 ng/mL in blood) to guarantee detectable 
tissue levels. 
In order to analyze the in vitro-in vivo correlation, the excipient was set at an 
excipient-blood ratio of 1:200. This concentration was found to be non-hemolytic 
in vitro for selected excipients except TPGS which induced hemolysis after a longer 
contact time. To rule out any changes caused by cell lysis, TPGS investigations were 
carried out in the non-hemolytic range. The excipient concentration of 0.5% also 
correlates to the normal dosing range estimated for an intravenous bolus injection in 
mice and rats, assuming a blood volume of ~70 mL/kg and an injection volume of 
<3 mL/kg. However, in humans according to the literature (54), excipient 
concentrations above 0.1% in blood are regarded as high and generally only 
obtained following intravenous infusions. Considering marketed injectable 
formulations for example, the amount of excipient in blood is up to 0.15% HP-β-CyD 
(Sporanox) and 0.3-0.5% CEL (Vumon and Taxol respectively). 
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Table 5-1 Overview of model compounds  
Physicochemical (PC) and pharmacokinetic (PK) properties of model compounds selected for investigating drug-excipient interactions in blood 
Compound COM1 COM2 COM3 COM4 COM5 
 PET ligand PET ligand NCE NCE NCE 
 
Chemical structure 
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PC properties 
     
MW (g/mol) 240 410 295 <400 533 
LogD 6.8 3.4 4.5 2.3 1.7 3.7 
pKa 3.8 5.7 4.1, 8.7 3.2, 4.6 10.6 
H20 solubility, pH 6.8 (mg/L) 20 <2.5 4000 <500 100 
PSA (Å2) 35 50 25 63 166 
H-bond acceptors 3 5 3 4 12 
H-bond donors 0 0 0 1 3 
Critical value(s) Solubility (base) Solubility   MW, PSA, H-bond acc. 
PK parameters 
     
Species Rat Mouse Rat Rat Rat 
In vitro: 
     
 Fraction in plasma (%) 75 45 20 ~100 80 
 Free in plasma (%) 2.1 1.8 12 2.4 11 
 Major binding protein Albumin > AGP Albumin > LP AGP > Albumin Albumin > AGP Albumin ≈ AGP 
In vivo: 
     
 Matrix Plasma Blood Blood Plasma Plasma 
 t1/2 (h) 0.08 1.1 1.1 10 0.4 
 CL (mL/min/kg) 202 10  142 0.4 7.2 
 Vss (L/kg) 11 14 10 0.3 0.3 
 funchanged (%) 1.4 49 14 98 94 
AGP: α1-acid glycoprotein, CL: Drug clearance, funchanged: Fraction of unchanged drug based on AUC ratio of parent drug and total radioactivity, LogD: Logarithm of octanol-water distribution 
coefficient, LP: Lipoproteins, MW: Molecular weight, NCE: New chemical entity, pKa: Negative logarithm of dissociation constant, PSA: Polar surface area, t1/2: Main elimination half-life, Vss: Volume 
of distribution under steady-state conditions 
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In trying to evaluate the potential of excipients to affect partition parameters in 
blood, selected excipients were screened in vitro for interactions with the model 
compounds using a blood distribution method and protein binding assays 
(ultrafiltration/ultracentrifugation). The most interacting excipients were subsequently 
taken forward for in vivo studies in animals given a single iv dose to ascertain 
whether there was a change in pharmacokinetics, and whether an in vitro-in vivo 
correlation existed. 
Amongst the excipients tested, the excipient PEG 200 was not active as an 
interacting agent, whereas the others were more or less active (Table 5-2). However, 
there was no apparent relationship between the nature of interactions and the 
compound properties. 
TPGS was found in vitro to enhance the plasma fraction of COM1 and COM2 in 
blood, and higher plasma concentrations were associated with a decrease of 
compound unbound in plasma. A significant increase in plasma concentrations of 
parent drug (2-fold) and metabolites (4-fold) were observed following intravenous 
administration of COM2 in mice, and t1/2 of COM2 remained unchanged, whereas t1/2 
of metabolites was 4-fold higher. While TPGS led to similar trends of COM1-related 
metabolites after injection in rats, values determined for parent drug were 
inconsistent with those obtained in vitro. A very extensive metabolism coupled to fast 
elimination was detected for COM1 which led to a stop in additional investigations to 
understand the in vitro-in vivo discrepancy. 
The use of CEL and Solutol in rats reduced in vitro the binding of COM4 and COM5 
to plasma proteins, and the higher free drug fraction was accompanied by enhanced 
partitioning into blood cells. Both excipients led to 2-fold higher unbound plasma 
concentrations following iv administration of COM4 formulated in CEL and COM5 in a 
Solutol-containing solution. Systemic and tissue levels of COM4 remained 
unaffected. In contrast, dosing COM5 in Solutol resulted in an earlier increase of 
blood-plasma concentration ratios, indicating enhanced uptake into blood cells. Later 
on, COM5 concentrations in blood and plasma were significantly enhanced to a 
similar extent (2-fold) yielding ratios equalized to control values. The systemic 
accumulation was correlated to higher t1/2 (2-fold). The AUC of COM5 in muscle and 
skin increased going along with a raise of t1/2 in muscle and none in skin.  
In vitro, HP-β-CyD increased the amount of COM3 distributed into rat plasma and 
lowered the binding to plasma proteins. Concentration ratios were only about 1/2 for 
blood-plasma and 1/8 for blood cell-unbound in plasma as compared to reference 
values. At earlier time points after iv dosing, concentrations of COM3 in blood and 
plasma were lower in the presence of HP-β-CyD (~2/3 of control), whereas over 
30-fold higher levels of COM3 in urine were found. Subsequently, tissue 
concentrations and tissue-blood concentration ratios of COM3 with HP-β-CyD were 
significantly decreased. 
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Table 5-2 Qualitative impact of excipients on pharmacokinetic parameters  
Excipient-compound interactions obtained after in vitro incubations and after intravenous administration in animals using excipients at ~0.5% in blood and 
compounds at a dose of either ~1 nmol/kg (COM1, COM2) or ~1 µmol/kg (COM3, COM4, COM5). Arrows indicate excipient-induced changes compared to 
the excipient-free group (↔: no changes, ↑: increase, ↓: decrease). 
Compound Excipient Species Changes  Comments 
   
In vitro In vivo 
 
COM1 Vit. E TPGS Rat ↑ Accumulation in plasma ↓ Plasma protein binding • No changes in vitro at ≤0.5% TPGS 
   
↓ Partitioning into blood cells ↓ AUC0.08-0.5h • Similar AUCs of drug free in plasma 
   
↑ Plasma protein binding  ↓ C0 • Increase in AUC of metabolites 
    
↔ t1/2 • Inappropriate model compound due  
    
↔ Tissue distribution to rapid metabolism/elimination 
COM2 Vit. E TPGS Mice ↑ Accumulation in plasma ↑ AUC0.08-1h  • ↑ AUC and ↑ t1/2 of metabolites 
   
↓ Partitioning into blood cells ↑ C0  • Ex vivo protein binding not available 
   
↑ Plasma protein binding ↔ t1/2 due to values <LOQ 
   
 ↔ Tissue distribution  
COM3 HP-β-cyclodextrin Rat ↑ Accumulation in plasma ↓ Plasma protein binding  
   
↓ Partitioning into blood cells ↓ AUC0.08-1h  
   
↓ Plasma protein binding ↓ C0   
    
↔ t1/2  
    
↓ Skin concentrations  
    
↑ Urinary excretion  
COM4 Cremophor EL Rat ↓ Accumulation in plasma ↓ Plasma protein binding  
   
↑ Partitioning into blood cells ↔ AUC0.08-1h   
   
↓ Plasma protein binding ↔ C0   
    
↔ t1/2  
    
↔ Tissue distribution  
COM5 Solutol HS 15 Rat ↓ Accumulation in plasma ↓ Plasma protein binding  
   
↑ Partitioning into blood cells ↑ AUC0.08-1h  
   
↓ Plasma protein binding ↔ C0  
   
 ↑ t1/2  
   
 ↑ Muscle/skin concentrations  
AUC: Area under the plasma drug concentration-time curve, C0: Initial plasma concentration at time zero, LOQ: Limit of quantification, t1/2: Half-life in plasma using the last three data points  
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These results clearly show the role of excipients as a modulator of the protein 
binding and cellular partitioning of compounds in blood which can impact the overall 
drug disposition. Excipient-induced changes in the free fraction and cell uptake of 
drugs within the blood compartment are explained by various mechanisms 
(Figure 5-1). An excipient is able to influence the fraction of a co-administered drug in 
plasma and blood cells by direct drug interactions and/or interferences with blood 
components such as proteins and cell constituents, particularly membranes. 
Consequently, bound and free concentrations in plasma and cellular concentrations 
may be shifted, potentially contributing to a “new” steady state. Altered plasma 
concentrations can be the result of changes in drug protein binding, drug adsorption 
to excipients, and/or drug trapping into excipient micelles or complexes. Whichever 
effect dominates, more drug can be free or bound, thereby accounting for the amount 
of drug available for cellular partitioning. Excipients could also vary the uptake into 
blood cells due to alterations in membrane structure and/or drug presentation, both 
mechanisms either facilitating or hindering drug transport via membranes. In the end, 
most likely different interacting processes contribute to the final effect depending on 
the force and nature of each single interaction. 
 
Free drug Free drug
Bound drug
Protein-bound drug
Excipient-drug interactions
(solubilization, adsorption, incorporation)
(destruction, adsorption, 
integration, penetration)
PLASMA BLOOD CELLS
Excipient-membrane interactionsExcipient-protein interactions
(destruction, adsorption, binding)
 
Figure 5-1 Mechanisms underlying alterations in drug partition parameters in blood 
The presence of excipients in blood may influence drug levels in plasma (protein-bound and free 
fraction) and blood cells by interacting with the drug or blood components, thereby either blocking or 
promoting the protein binding and/or the drug available for cellular partitioning. 
 
Analyzing the in vitro with the in vivo situation, the effect of selected excipients on 
the protein binding showed a good in vitro-in vivo correlation, whereas systemic 
concentrations after iv administration in animals could often not be predicted well 
from in vitro data. In contrast to in vitro assays reflecting stationary conditions, the 
in vivo situation entails processes running in an open and dynamic system, thereby 
involving not only distribution but also elimination. This can initiate shifts in the 
systemic drug exposure and be responsible for the absence of a direct correlation to 
blood/plasma concentrations and thus to pharmacokinetic parameters as well. Apart 
from this, the effective excipient concentration achieved in vivo in the circulation is 
usually unknown and may differ from concentrations applied in vitro. Although 
excipient concentrations can be theoretically estimated using blood volume, dose, 
and application volume, values are fairly arbitrary because excipient levels decline 
most likely fast in the body due to dilution and degradation within the blood 
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compartment. This suggests that if alterations in blood partitioning occur following 
administration in vivo, they should be best detectable at times shortly post-dose. 
Even though differences between the in vitro and in vivo results were found, the 
in vitro test can serve as a straightforward tool for rapid detection of excipient-drug 
interactions in blood while requiring little amounts of drug. As a result, the 
determination of in vitro blood partition parameters is proposed as a rough estimator 
of a possible potential of excipients to contribute to pharmacokinetics of parenteral 
drugs. In addition to the blood-to-plasma distribution ratio, the protein binding 
provides useful information to elucidate excipient-induced alterations and allows the 
calculation of the blood cell-to-free in plasma distribution ratio. These data help not 
only to optimize the proper evaluation of pharmacokinetics in animals, but also to 
enable a more rational approach in the development of formulations for drug 
candidates. Therefore, the in vitro investigation of blood distribution and protein 
binding with and without excipient is recommended at a very early preclinical stage in 
cases where animal pharmacokinetics of lower dosed compounds (e.g. PET ligands) 
must be examined from excipient-containing solutions (e.g. surfactants, complexing 
agents). The influence assessment of excipients may also be a promising formulation 
approach for iv solutions of non-ionizable, lipophilic, and nonpolar molecules which 
are very challenging to formulate appropriately due to poor water solubility (e.g. 
paclitaxel, docetaxel, cyclosporin). 
Figure 5-2 illustrates a possible formulation procedure that integrates data 
generated by in vitro investigations in blood. Cosolvents, complexing agents, 
surfactants, and combinations of these excipients are frequently used to dissolve a 
compound for intravenous administration in animals. Method(s) are chosen 
considering available compound characteristics such as physicochemical and 
pharmacokinetic properties, doses, and clinical objectives. If an appropriate 
formulation in terms of solubility and stability is found, blood distribution and protein 
binding studies are performed both in the presence and absence (reference) of 
excipient(s) using in vitro assays. Protein binding studies should mainly be 
considered if the extent of binding can be appropriately determined by ultrafiltration, 
dialysis, or ultracentrifugation, all three conventional and simple methods. Next, 
partition parameters (FP, fu, BPR, BCPR, and ρ) are evaluated and compared to 
those obtained for the reference formulation representing an excipient-free solution 
(e.g. glucose 5% or saline including pH adjustment, buffer, blank plasma). 
Formulations are ranked in order of changes relative to the reference. As a result, a 
formulation can be modified, adapted, or selected for intravenous administration in 
animals. In cases where the in vivo administration requires the addition of 
excipient(s) to the reference formulation to solubilize the compound, the formulation 
must be tested in vitro. The formulation is an acceptable in vivo reference if the 
in vitro parameters are similar to those of the excipient-free solution, i.e. the in vitro 
reference. The outcome of the in vivo study triggers formulation optimization to 
minimize or abolish excipient effects, further investigation to better interpret data, or 
formulation acceptance for in vivo dosing and formulation development. Finally, it 
should be possible to exclude or at least be aware of a potential impact of 
excipient(s) on the drug disposition. Data can also be applied to identify both the 
activity of a certain excipient with different compounds and the excipient sensitivity of 
compounds with similar properties.  
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Figure 5-2 Suggested flow chart for an iv formulation development strategy 
 
In conclusion, substantial drug-excipient interactions in animals have been 
identified for different excipients commonly used in drug formulation and 
pharmacologically active compounds with diverse properties. These findings support 
the assumption that certain excipients are not “inert” but are “functional” excipients 
and are able to alter the disposition of co-administered drugs. Such data need 
special attention since excipient-related changes may occur with similar or other 
drug/excipient formulations. Identifying excipient-drug interactions and understanding 
how excipients affect the drug behavior will assist in the pharmacokinetic 
characterization and the formulation development/optimization of drug candidates in 
development. Furthermore, a better knowledge of the relationship between drug, 
excipient, and blood constituents suggests new approaches in drug development in 
terms of controlling the pharmacokinetic profile by the right choice of excipient and its 
amount. This may enable to better anticipate the target of different blood and body 
compartments without extensive animal and human tests, potentially resulting in 
modulated pharmacological responses. 
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6 Outlook 
The results of this work demonstrated the ability of commonly used injectable 
excipients, especially CEL, HP-β-CyD, and SHS, to influence pharmacokinetic 
parameters in blood, consequently contributing to altered drug disposition following iv 
dosing. However, to increase the knowledge of drug-excipient interactions, additional 
studies are required to confirm the above findings with further drug/excipient 
formulations, and with an emphasis on the role of excipients per se in 
pharmacokinetics of parenteral drugs. 
 
 The excipients were tested in vitro and in vivo at a fixed concentration of 0.5% in 
blood, being within the normal range for animal injections and higher for clinical 
ones. 
Investigations by varying the excipient amount would give insight into the 
concentration-effect relationship and potency of excipients. Examination of lower 
excipient levels should also give an indication about the relevance and impact of 
excipient-induced alterations on applications in humans. 
 
 No direct correlation between the interacting excipient and the compound 
properties were found, and no trends could be apparently observed in changes 
regarding the excipient characteristics.  
Continued investigations are necessary to elucidate whether observed 
phenomena are associated with certain drugs or more by some drug classes 
characterized by specific physicochemical properties. Focusing on excipients, it 
would be of interest to explore more in detail the frequency and significance of 
interactions and the excipient preference in terms of particular changes. 
 
 The emphasis throughout the current work was placed on providing an insight into 
excipient-triggered effects and their in vitro-in vivo correlation. According to the 
literature, little is known about mechanisms underlying these alterations taking into 
account in vitro-in vivo investigations (94,110,112).  
To explain findings and improve excipient characterization, further investigations 
should focus on the mechanistic basis for the role of excipients in protein binding, 
blood/plasma partitioning, and cellular distribution using in vitro assays appropriate 
to understand the observed effects. In addition, modification of in vitro approaches 
could facilitate correlation of effects and mechanisms determined in vitro with in 
vivo situations, increase the understanding of in vitro-in vivo relationships, and 
enable extrapolation of in vitro results to in vivo pharmacokinetics. A better in vitro-
in vivo correlation could also reduce in vivo studies and may contribute to more 
efficient drug development. 
 
 There are drug-drug interactions reported in the literature where drugs were 
administered intravenously in conjunction with excipient-containing formulation of 
other drugs (e.g. valspodar formulated in CEL) (108,109). Most likely, the 
presence of excipient(s) in drug formulations contributed to observed 
pharmacokinetic interactions.  
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The research into the potential of excipients to induce kinetic alterations of agents 
administered intravenously in conjunction with excipient-containing formulation of 
other compounds should lead to a deeper insight into drug-drug interactions. 
These data may provide helpful information relevant for safety issues, dosage 
planning, and treatment optimization in clinical drug monitoring. 
 
 Further studies could focus on the potential clinical significance of drug-excipient 
interactions observed in animals. 
 
Finally, ongoing efforts for a proper understanding of excipients as biologically and 
pharmacologically active compounds will allow a better control of designing 
formulations with optimal characteristics for a better drug therapy. 
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8 Appendix 
 
Raw data of COM1 in rat 
In vitro blood distribution of [3H]COM1 using blood pools with different hematocrits: 
Total radioactivity concentration determined in blood and plasma 
Excipient  Nominal COM1 H Incubation Actual values 
 
 
in blood  time (pg-eq/mL, mean ±SD, n=3*) 
  % in blood (pg/mL)  (min) Blood Plasma 
None  60 0.48 0 53 ± 1 76 ± 1 
(Glu)    5 53 ± 1 75 ± 0 
    10 52 ± 1 74 ± 1 
    20 52 ± 0 74 ± 1 
  6000  0 5335 ± 80 7835 ± 121 
    5 5637 ± 116 7784 ± 103 
    10 5576 ± 40 7598 ± 114 
    20 5502 ± 76 7502 ± 98 
HP-β-CyD 0.5 60 0.48 0 62 ± 1 97 ± 0 
    5 62 ± 1 96 ± 1 
    10 62 ± 1 94 ± 1 
    20 62 ± 0 93 ± 1 
  6000  0 6564 ± 21 10052 ± 31 
    5 6550 ± 30 10057 ± 214 
    10 6434 ± 85 9896 ± 66 
    20 6280 ± 213 9918 ± 80 
 5 60 0.45 0 64 ± 0 102 ± 1 
    5 65 ± 1 102 ± 1 
    10 63 ± 1 102 ± 1 
    20 64 ± 1 101 ± 1 
  6000  0 6516 ± 132 10660 ± 26 
    5 6598 ± 273 10762 ± 382 
    10 6475 ± 288 10454 ± 163 
    20 6653 ± 79 10482 ± 130 
SHS 0.5 60 0.48 0 60 ± 2 86 ± 2 
    5 60 ± 0 94 ± 19 
    10 60 ± 1 81 ± 1 
    20 60 ± 0 81 ± 1 
  6000  0 6265 ± 40 8845 ± 102 
    5 6240 ± 92 8562 ± 44 
    10 6127 ± 110 8432 ± 35 
    20 6104 ± 112 8109 ± 122 
 5 60 0.45 0 59 ± 1 93 ± 1 
    5 58 ± 1 92 ± 0 
    10 56 ± 1 91 ± 1 
    20 58 ± 1 91 ± 1 
  6000  0 6166 ± 65 9908 ± 44 
    5 6180 ± 162 9607 ± 123 
    10 6230 ± 99 9529 ± 119 
    20 6189 ± 104 9489 ± 211 
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In vitro blood distribution of [3H]COM1 continued 
Excipient  Nominal COM1 H Incubation Actual values 
 
 
in blood  time (pg-eq/mL, mean ±SD, n=3*) 
  % in blood (pg/mL)  (min) Blood Plasma 
TPGS 0.5 60 0.48 0 59 ± 1 92 ± 1 
    5 58 ± 1 90 ± 1 
    10 58 ± 1 88 ± 2 
    20 58 ± 0 87 ± 1 
  6000  0 5494 ± 102 8949 ± 87 
    5 5518 ± 124 8549 ± 165 
    10 5552 ± 74 8387 ± 101 
    20 5431 ± 23 8286 ± 71 
 5 60 0.40 0 50 ± 1 81 ± 1 
    5 50 ± 1 80 ± 1 
    10 50 ± 0 79 ± 1 
    20 50 ± 1 72 ± 1 
  6000  0 5042 ± 20 8175 ± 148 
    5 5014 ± 34 7907 ± 136 
    10 5102 ± 59 7952 ± 77 
    20 5069 ± 68 7204 ± 35 
*: Triplicate analyses were conducted on one aliquot for each time point 
 
 
In vitro protein binding of [3H]COM1 using the same plasma pool: 
Total radioactivity concentration determined in plasma and ultrafiltrate samples 
Excipient  Nominal COM1 Actual values (pg-eq/mL) 
 % in plasma (pg/mL) Plasma* Ultrafiltrate 
None  60 65 2.6 
(Glu)    2.6 
    2.6 
  6000 6302 270 
    268 
    272 
TPGS 0.5 60 62 2.7 
  
 
 
 2.1 
    2.9 
  6000 5708 171 
    230 
    133 
 5 60 67 1.2 
    1.3 
    1.1 
  6000 5886 187 
    103 
    68 
*: Mean of duplicate determination of plasma spiked with different COM1 stock solutions 
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Tissue and plasma levels of parent drug and total radioactivity after iv administration of 
[3H]COM1 (4 µg/kg) in the control group 
Time  Tissue  Individual concentration values 
(h)  COM1 (pg/g)  Radioactivity (pg-eq/g) 
0.08  Plasma* 866 381 958  2529 1871 2052 
 Lung 2012 1440 1867  3431 2224 2538 
 Heart 2366 973 1619  2593 1490 1808 
 Liver 1069 384 724  11805 9501 10699 
 Kidney 2263 995 1692  6350 5770 5281 
 Fat 2803 1982 4753  2638 2213 4859 
 Muscle 1405 811 1234  1312 882 1172 
 Skin 433 225 296  937 524 583 
 Brain 6229 4525 4712  5431 4004 4053 
0.25 Plasma* 275 257 178  1719 1482 1366 
 Lung 399 607 518  1491 1378 1374 
 Heart 517 645 285  1034 1023 778 
 Liver 274 511 238  7904 6502 6920 
 Kidney 557 664 321  5270 5046 5425 
 Fat 6508 5897 4206  5953 5307 4112 
 Muscle 565 574 306  659 686 463 
 Skin 228 213 219  581 702 570 
 Brain 3407 4085 3014  3033 3552 2719 
0.5 Plasma* 179 103 101  1525 1442 1379 
 Lung 622 367 335  1365 1089 1030 
 Heart 310 211 214  684 684 661 
 Liver 138 71 100  7090 5263 4993 
 Kidney 345 220 202  4924 4585 5053 
 Fat 8008 4790 4248  6586 4071 3649 
 Muscle 270 159 166  409 349 342 
 Skin 199 64 104  559 449 480 
 Brain 2676 2419 2123  2310 2180 1953 
*: pg/mL and pg-eq/mL 
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Tissue and plasma levels of parent drug and total radioactivity after iv administration of 
[3H]COM1 (4 µg/kg) in the TPGS group 
Time  Tissue  Individual concentration values 
 (h)  COM1 (pg/g)  Radioactivity (pg-eq/g) 
0.08 Plasma* 312 297 278  2842 2939 3006 
 Lung 1370 1173 1560  2364 2057 2272 
 Heart 1190 971 912  1584 1262 1291 
 Liver 449 234 337  10459 8898 10720 
 Kidney 1012 768 806  5047 4767 4829 
 Fat 2182 1485 1860  2712 2380 1703 
 Muscle 845 726 1132  880 720 1046 
 Skin 100 45 53  665 351 343 
 Brain 4072 2765 3083  3816 2353 2709 
0.25 Plasma* 89 107 121  2040 2440 2368 
 Lung 531 688 546  1343 1488 1356 
 Heart 351 471 454  737 864 851 
 Liver 104 205 170  5354 6770 5184 
 Kidney 321 435 446  6931 4972 6603 
 Fat 1352 3916 1578  1456 4764 2035 
 Muscle 355 649 588  532 789 675 
 Skin 71 72 37  563 518 342 
 Brain 1811 2327 1955  1648 2017 1841 
0.5 Plasma* 35 65 61  2027 2054 2186 
 Lung 214 195 319  1172 1067 1115 
 Heart 167 207 250  539 566 650 
 Liver 75 70 117  4225 4417 4314 
 Kidney 197 209 215  6923 6364 5600 
 Fat 3406 2067 2295  3071 1625 2734 
 Muscle 191 226 256  343 394 368 
 Skin 120 52 41  515 389 398 
 Brain 1516 1332 1541  1413 1295 1480 
*: pg/mL and pg-eq/mL 
 
 
Ex vivo protein binding of [3H]COM1 in the control and TPGS group: 
Parent drug concentration determined in plasma and ultrafiltrate 
 
Dose Time Individual values (pg/mL) 
 
(µg/kg) (h) Plasma*  Ultrafiltrate 
Control group 4 0.08 794  16.9 16.9 
 
 0.25 249  5.5 5.1 
 
 0.50 137  2.7 2.6 
TPGS group 2.7 0.08 331  12.7 12.0 
  0.25 120  4.1 4.4 
  0.50 60  2.5 2.4 
*: Mean of duplicate determination of plasma pooled for each time point 
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Raw data of COM2 in mouse 
In vitro blood distribution of [3H]COM2 using blood pools with different hematocrits: 
Total radioactivity concentration determined in blood and plasma 
Excipient Nominal COM2 H Incubation Actual values 
 in blood  time (pg-eq/mL, mean ±SD, n=3*) 
 (pg/mL)  (min) Blood Plasma 
None** 100 0.45 5 115 ± 2 85 ± 3 
(Glu)   60 115 ± 5 93 ± 4 
   240 112 ± 6 101 ± 2 
CEL/EtOH, 65:35 100 0.45 5 104 ± 5 86 ± 4 
   60 105 ± 2 83 ± 1 
   240 102 ± 1 87 ± 6 
 100’000 0.46 5 103797 ± 1430 83684 ± 1446 
   60 102979 ± 1547 81784 ± 896 
   240 105912 ± 2594 80887 ± 998 
HP-β-CyD 100 0.45 5 103 ± 5 88 ± 2 
   60 104 ± 5 94 ± 1 
   240 99 ± 2 94 ± 7 
 100’000 0.43 5 105176 ± 1165 92396 ± 1519 
   60 104609 ± 1238 95791 ± 668 
   240 107331 ± 880 96454 ± 1780 
SHS 100 0.45 5 101 ± 1 86 ± 1 
   60 99 ± 4 85 ± 1 
   240 105 ± 3 84 ± 3 
 100’000 0.44 5 118080 ± 891 99140 ± 1915 
   60 116422 ± 2822 93052 ± 1190 
   240 116363 ± 890 89790 ± 1735 
PEG 200 100 0.45 5 124 ± 4 96 ± 1 
   60 125 ± 6 95 ± 2 
   240 122 ± 2 103 ± 5 
 100’000 0.46 5 112001 ± 3923 87146 ± 1273 
   60 112161 ± 1189 89801 ± 1646 
   240 110680 ± 652 90561 ± 1883 
TPGS 100 0.45 5 101 ± 2 115 ± 2 
   60 104 ± 2 101 ± 1 
   240 101 ± 3 95 ± 3 
 100’000 0.43 5 100911 ± 1443 106192 ± 992 
   60 100608 ± 3207 88758 ± 1037 
   240 100236 ± 4088 81755 ± 810 
*: Triplicate analyses were conducted on one aliquot for each time point, **: similar to previous study 
  
In vitro protein binding of [3H]COM2 at 10 ng/mL using the same plasma pool:  
Parent drug concentration determined in plasma and ultracentrifugate 
Excipient  Actual values (pg/mL) 
 % in plasma Plasma Ultracentrifugate 
None  9649 166 
(plasma)  9278 164 
  9162 164 
  9292 164 
TPGS 0.5 8624 116 
  8651 124 
  8722 103 
  8739 99 
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Tissue and plasma levels of parent drug and total radioactivity after iv administration of 
[3H]COM2 (0.4 µg/kg) in the control group 
Time Tissue  Individual concentration values 
 (h)  COM2 (pg/g)  Radioactivity (pg-eq/g) 
0.08 Plasma* 110 112 91  181 194 164 
 Lung 1964 1955 1504  2450 2199 1704 
 Heart 796 830 623  1074 950 741 
 Liver 2398 2387 1778  3112 3022 2360 
 Kidney 2083 1871 1327  2276 2024 1511 
 Fat 140** 327 230  58** 540 603 
 Muscle 124 170 203  160 218 234 
 Skin 0** 35** 10**  14** 76** 32** 
 Brain 1155 1112 1018  1097 1086 1046 
0.25 Plasma* 94 71 77  164 141 139 
 Lung 1344 908 1365  1648 1849 1759 
 Heart 495 465 433  622 593 580 
 Liver 1579 1214 1549  2218 2161 2381 
 Kidney 1194 1075 1259  1468 1445 1518 
 Fat 714 459 778  1103 977 1218 
 Muscle 201 217 227  251 268 258 
 Skin 113** 16** 59**  160** 73** 114** 
 Brain 1060 1191 1345  1064 1150 1287 
0.5 Plasma* 60 58 58  119 113 111 
 Lung 720 703 842  1192 1444 1350 
 Heart 295 262 331  454 447 447 
 Liver 978 861 1040  1918 2348 2129 
 Kidney 757 753 932  1017 1303 1336 
 Fat 1014 602 973  1836 1164 2203 
 Muscle 187 167 189  242 252 231 
 Skin 87** 16** 18**  97** 129** 104** 
 Brain 1209 1006 1044  1160 1003 1044 
1 Plasma* 32 41 28  60 79 49 
 Lung 369 478 468  1465 1274 1171 
 Heart 154 199 205  347 377 364 
 Liver 591 618 534  2077 1736 1383 
 Kidney 471 522 451  1088 1020 846 
 Fat 496 444 713  1066 1458 1253 
 Muscle 103 80 91  171 169 146 
 Skin 0** 38** 48**  138** 123** 122** 
 Brain 673 832 688  826 902 806 
*: pg/mL and pg-eq/mL, **: value below LOQ 
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Tissue and plasma levels of parent drug and total radioactivity after iv administration of 
[3H]COM2 (0.4 µg/kg) in the TPGS group 
Time Tissue  Individual concentration values 
 (h)  COM2 (pg/g)  Radioactivity (pg-eq/g) 
0.08 Plasma* 223 248 268  506 549 606 
 Lung 1789 1913 1880  2036 2137 2116 
 Heart 661 711 724  766 890 924 
 Liver 2331 2252 2360  2593 2585 2656 
 Kidney 1697 1831 1677  1815 2014 1839 
 Fat 246 150** 317  362 366 740 
 Muscle 108 190 272  144 246 330 
 Skin 0** 20** 60**  39** 36** 77** 
 Brain 913 1069 1133  904 1024 1080 
0.25 Plasma* 178 148 151  403 377 394 
 Lung 1522 1175 1133  1820 1412 1436 
 Heart 489 478 452  593 597 578 
 Liver 1636 1743 1500  2243 2293 2130 
 Kidney 1112 1114 1256  1387 1415 1513 
 Fat 932 915 1480  1742 1392 2239 
 Muscle 237 222 183  290 288 283 
 Skin 23** 0** 38**  144** 140** 96** 
 Brain 1088 1244 1207  1004 1150 1166 
0.5 Plasma* 111 118 143  330 359 421 
 Lung 890 911 968  1292 1728 1599 
 Heart 292 385 384  420 630 570 
 Liver 1086 1200 1128  1901 2342 2002 
 Kidney 864 996 1103  1124 1584 1452 
 Fat 1393 ―*** 765  1492 ―*** 1576 
 Muscle 156 181 173  232 273 269 
 Skin 44** 73** 114**  106** 131** 192** 
 Brain 1048 1272 1325  1003 1298 1237 
1 Plasma* 79 97 63  333 296 264 
 Lung 669 885 512  1672 1588 1769 
 Heart 231 285 143  519 483 423 
 Liver 774 1028 798  2073 1946 2394 
 Kidney 726 835 659  1431 1342 1374 
 Fat ―*** 320 688  ―*** 1036 1712 
 Muscle 143 137 76  210 240 221 
 Skin 30** 147** 52**  158** 220** 194** 
 Brain 1141 1188 889  1204 1202 1070 
*: pg/mL and pg-eq/mL; **: value below LOQ, ***: no fat dissectible 
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Raw data of COM3 in rat 
In vitro blood distribution of [3H]COM3 using the same blood pool (H 0.44): 
Total radioactivity concentration determined in blood and plasma 
Excipient Nominal COM3 Incubation Actual values 
 in blood time (ng-eq/mL, mean ±SD, n=3*) 
 (ng/mL) (min) Blood Plasma 
None 5 5 4.6 ± 0.3 1.7 ± 0 
(Glu)  30 4.6 ± 0.2 1.7 ± 0.1 
  60 4.7 ± 0.4 1.7 ± 0.1 
 500 5 511 ± 2 179 ± 0 
  30 507 ± 6 178 ± 2 
  60 512 ± 9 176 ± 2 
CEL/EtOH, 65:35 5 5 4.9 ± 0.4 1.8 ± 0.1 
  30 4.9 ± 0.3 1.7 ± 0 
  60 5.1 ± 0.2 1.7 ± 0 
 500 5 516 ± 6 161 ± 2 
  30 508 ± 2 160 ± 1 
  60 508 ± 9 156 ± 1 
HP-β-CyD 5 5 5.3 ± 0.2 3.5 ± 0.1 
  30 5.2 ± 0.4 3.5 ± 0.1 
  60 5.1 ± 0 3.6 ± 0.1 
 500 5 516 ± 5 324 ± 2 
  30 510 ± 2 320 ± 5 
  60 512 ± 4 326 ± 2 
SHS 5 5 4.9 ± 0.2 1.4 ± 0 
  30 4.7 ± 0.1 1.5 ± 0 
  60 4.9 ± 0.3 1.6 ± 0 
 500 5 498 ± 10 143 ± 0 
  30 506 ± 14 143 ± 3 
  60 498 ± 1 144 ± 1 
PEG 200 5 5 4.9 ± 0.4 1.7 ± 0.1 
  30 5.1 ± 0.1 1.7 ± 0.1 
  60 4.8 ± 0.1 1.8 ± 0.1 
 500 5 520 ± 7 169 ± 1 
  30 510 ± 9 170 ± 2 
  60 518 ± 6 176 ± 3 
EtOH/PEG200/Glu, 5 5 4.6 ± 0.3 1.8 ± 0.1 
5:5:90  30 4.3 ± 0.2 1.8 ± 0.1 
  60 4.4 ± 0.1 1.8 ± 0.1 
 500 5 535 ± 10 188 ± 1 
  30 535 ± 10 194 ± 2 
  60 538 ± 8 192 ± 1 
TPGS 5 5 5.2 ± 0.3 2.3 ± 0 
  30 5.1 ± 0 2.2 ± 0.1 
  60 5.1 ± 0 2.4 ± 0.3 
 500 5 546 ± 3 231 ± 3 
  30 542 ± 6 231 ± 2 
  60 551 ± 5 231 ± 2 
*: Triplicate analyses were conducted on one aliquot for each time point 
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In vitro protein binding of [3H]COM3 using the same plasma pool: 
Excipient Nominal COM3 Actual values 
 
in plasma (ng-eq/mL) 
 
(ng/mL) Plasma* Ultrafiltrate 
None 5 5.8 0.67 
(Glu)   0.76 
 
  0.68 
 
500 512 63 
 
  63 
 
  62 
HP-β-CyD 5 5.4 2.2 
 
 
 2.1 
 
  2.2 
 
500 538 214 
 
  216 
 
  209 
EtOH/PEG200/Glu 5%, 5:5:90 5 5.2 0.66 
 
 
 0.67 
 
  0.65 
 
500 552 66 
 
  66 
 
  64 
*: Mean of duplicate determination of plasma spiked with different COM3 stock solutions 
 
 
 
Ex vivo protein binding of [3H]COM3 in the control and HP-β-CyD group: 
Parent drug concentration determined in plasma & ultrafiltrate 
 
Time Individual values (pg/mL) 
 
(h) Plasma* Ultrafiltrate 
Control group 0.08 16.8 1.1 1.3 
 0.5 4.6 0.4  
 1 3.5 0.3  
HP-β-CyD group 0.08 9.7 2.5 2.3 
 0.5 5.4 0.8 0.7 
 1 3.4 0.2 0.3 
*: Mean of duplicate determination of plasma pooled for each time point 
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Circulation and tissue levels of parent drug and total radioactivity after iv administration of 
[3H]COM3 (0.3 mg/kg) in the control group 
Time Tissue  Individual concentration values 
 (h)  COM3 (ng/g)  Radioactivity (ng-eq/g) 
0.08 Blood* 39 42 57  60 63 81 
 Plasma* 15 19 19  38 40 41 
 Liver 1196 1394 1645  2097 2517 2767 
 Kidney 1760 1646 2019  2354 2286 2677 
 Fat 152 137 95  193 176 97 
 Heart 536 534 722  668 676 927 
 Lung 5712 5711 7113  8073 7897 9688 
 Muscle 152 112 105  161 112 98 
 Skin 209 139 85  216 136 86 
 Brain 1048 1062 1382  1323 1334 1736 
0.5 Blood* 20 13 18  75 85 83 
 Plasma* 8 5 6  89 115 104 
 Liver 644 419 700  2619 2716 2654 
 Kidney 671 400 692  1162 843 1144 
 Fat 66 45 59  89 80 83 
 Heart 210 125 199  296 201 278 
 Lung 2425 1317 2267  3403 1811 2947 
 Muscle 222 98 144  282 144 185 
 Skin 103 81 99  131 119 164 
 Brain 1002 803 909  1260 996 1164 
1 Blood* 11 11 10  80 70 60 
 Plasma* 4 5 4  105 99 74 
 Liver 383 427 373  1866 2152 2030 
 Kidney 345 405 320  707 758 659 
 Fat 30 31 33  49 52 53 
 Heart 106 126 102  161 188 157 
 Lung 1158 1092 1340  1680 1539 1817 
 Muscle 96 109 92  154 167 149 
 Skin 55 85 63  118 148 129 
 Brain 647 691 622  811 875 775 
*: pg/mL and pg-eq/mL 
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Circulation and tissue levels of parent drug and total radioactivity after iv administration of 
[3H]COM3 (0.3 mg/kg) in the HP-β-CyD group 
Time Tissue  Individual concentration values 
 (h)  COM3 (ng/g)  Radioactivity (ng-eq/g) 
0.08 Blood* 34 31 32  53 52 48 
 Plasma* 12 10 10  29 32 28 
 Liver 850 1052 1271  1181 1665 1901 
 Kidney 1413 1330 1474  1770 1611 1778 
 Fat 68 85 103  70 99 121 
 Heart 592 500 598  719 593 725 
 Lung 4669 4377 4739  6069 5352 5939 
 Muscle 151 147 129  159 157 129 
 Skin 84 64 nd**  66 49 nd** 
 Brain 954 990 908  1125 1165 1087 
0.5 Blood* 19 18 17  74 70 82 
 Plasma* 6 6 6  77 75 96 
 Liver 617 558 677  2110 2107 2159 
 Kidney 524 417 496  743 652 810 
 Fat 47 39 51  59 51 68 
 Heart 212 178 169  276 233 222 
 Lung 2355 2513 2258  2931 3032 2853 
 Muscle 137 137 116  172 169 143 
 Skin 32 37 50  52 65 135 
 Brain 733 743 822  895 864 958 
1 Blood* 11 10 10  65 69 71 
 Plasma* 4 3 4  77 87 92 
 Liver 344 nd** 336  1765 nd** 1597 
 Kidney 300 251 328  515 454 617 
 Fat 28 19 20  41 43 44 
 Heart 106 98 94  143 153 143 
 Lung 1257 926 976  1582 1205 1237 
 Muscle 98 98 59  133 161 84 
 Skin 29 27 23  49 110 68 
 Brain 606 604 588  734 726 697 
*: pg/mL and pg-eq/mL, **: not determined due to glas vial broken by homogenization   
 
 
In situ bladder catheterization of [14C]COM3 in the control and HP-β-CyD group: 
 
Time Urinary concentration Urine excreted 
 (h) COM3 (ng/mL) Radioactivity (ng-eq/mL) (g) 
Control 0.5 190 331  7226 13857  0.685 0.350  
group* 1 721 339  17998 12039  0.460 0.439  
 1.5 88 151  2855 7869  1.130 0.477  
 2 64 134  2435 9293  0.790 0.261  
HP-β-CyD  0.5 1911 5216 4903 3523 13028 12248 2.635 0.851 0.784 
group 1 7900 524 2965 44618 5086 27031 0.119 1.068 0.265 
 1.5 4209 899 1268 40724 18439 19080 0.111 0.188 0.267 
 2 1993 184 597 31856 7994 11100 0.124 0.412 0.335 
*: Rat N°3 died during in situ experiment 
 
  
75
Raw data of COM4 in rat 
In vitro blood distribution of [14C]COM4 at 100 ng/mL using the same blood pool (H 0.44): 
Total radioactivity concentration determined in blood and plasma 
Excipient  Incubation Actual values 
  time (ng-eq/mL, mean ±SD, n=3*) 
 % in blood (min) Blood Plasma 
None 0.5 5 98 ± 2 169 ± 0 
(saline)  30 98 ± 1 167 ± 1 
  60 98 ± 2 168 ± 3 
CEL 0.5 5 99 ± 0 147 ± 0 
  30 99 ± 2 135 ± 2 
  60 98 ± 1 128 ± 1 
 1 5 103 ± 1 139 ± 1 
  30 104 ± 0 125 ± 1 
  60 104 ± 2 120 ± 2 
HP-β-CyD 0.5 5 125 ± 2 202 ± 1 
  30 125 ± 1 201 ± 3 
  60 124 ± 0 199 ± 3 
 1 5 116 ± 2 171 ± 3 
  30 117 ± 3 171 ± 2 
  60 117 ± 2 170 ± 3 
SHS 0.5 5 110 ± 2 165 ± 2 
  30 110 ± 1 155 ± 1 
  60 110 ± 1 153 ± 3 
 1 5 112 ± 1 150 ± 2 
  30 112 ± 3 150 ± 1 
  60 112 ± 0 148 ± 2 
*: Triplicate analyses were conducted on one aliquot for each time point 
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In vitro protein binding of [14C]COM4 at 100 ng/mL using the same plasma pool: 
Total radioactivity concentration determined in plasma and ultrafiltrate 
Excipient  Actual values  
 
 (pg-eq/mL) 
 % in plasma Plasma* Ultrafiltrate 
None  97 2.5 
(saline)   2.3 
   2.2 
CEL 0.01 105 2.5 
   2.4 
   2.3 
 0.1 117 3.6 
   3.8 
   3.5 
 0.5 102 11.5 
   10.9 
   11.3 
 1 97 25.4 
   25.0 
   24.9 
HP-β-CyD 0.01 99 2.7 
   2.5 
   2.4 
 0.1 102 4.3 
   4.7 
   4.3 
 0.5 134 13.1 
   13.3 
   13.1 
 1 112 17.2 
   15.1 
   15.0 
SHS 0.01 99 2.5 
   2.2 
   2.2 
 0.1 101 3.4 
   3.1 
   3.3 
 0.5 116 11.5 
   11.1 
   11.2 
 1 112 17.1 
   17.4 
   16.7 
PEG 200  100 2.2 
   2.4 
   2.4 
TPGS  114 2.3 
   2.4 
   2.2 
*: Mean of duplicate determination of plasma spiked with different COM4 stock solutions 
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Circulation and tissue levels of total radioactivity after iv administration of [14C]COM4  
Time Tissue  Individual concentration values (ng-eq/g) 
 (h)  Control group  CEL group 
0.08 Blood* 1258 1855 1551  1340 1515 1556 
 Plasma* 2047 2761 2640  2211 2548 2517 
 Plasma water* 123 50 49  287 477 478 
 Lung 659 815 737  754 763 788 
 Muscle 216 228 222  251 230 250 
 Skin 348 229 253  229 227 307 
0.25 Blood* 1306 1202 1069  1350 1183 1414 
 Plasma* 2343 1983 1893  2357 1910 2273 
 Plasma water* 92 99 83  118 179 201 
 Lung 697 657 608  737 651 741 
 Muscle 206 215 205  204 212 216 
 Skin 443 317 330  351 402 432 
0.5 Blood* 1398 1431 1303  1394 1112 1142 
 Plasma* 2382 2543 2238  2357 1969 1926 
 Plasma water* 63 124 46  106 151 191 
 Lung 710 731 644  720 666 641 
 Muscle 202 206 197  204 203 204 
 Skin 363 426 436  384 389 343 
1 Blood* 1322 1189 1233  1329 732 1301 
 Plasma* 2297 1967 2049  2361 1192 2059 
 Plasma water* 35 101 99  99 106 186 
 Lung 649 618 616  674 539 674 
 Muscle 218 200 217  187 212 191 
 Skin 424 381 421  425 340 407 
*: ng-eq/mL 
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Raw data of COM5 
In vitro blood distribution of [14C]COM5 using blood pools with the same H 0.44: 
Total radioactivity concentration determined in blood and plasma 
Excipient Nominal COM5 Incubation Actual values 
 in blood time (ng-eq/mL, mean ±SD, n=3*) 
 (ng/mL) (min) Blood Plasma 
None 10 5 7.3 ± 0.6 11.5 ± 0.2 
(saline)  30 7.8 ± 0.2 11.8 ± 0.2 
  60 7.6 ± 0.7 11.8 ± 0.7 
 300 5 278 ± 2 386 ± 4 
  30 277 ± 0 391 ± 4 
  60 275 ± 7 384 ± 2 
EtOH 10 5 9.8 ± 0.6 13.8 ± 0.5 
  30 9.8 ± 0.6 13.5 ± 0.5 
  60 9.2 ± 0.6 13.9 ± 0.1 
 300 5 286 ± 2 404 ± 3 
  30 287 ± 6 400 ± 4 
  60 284 ± 5 395 ± 3 
CEL/EtOH, 65:35 10 5 8.8 ± 0.3 12.9 ± 0.6 
  30 9.1 ± 0.5 12.8 ± 0.3 
  60 9.2 ± 0.3 11 ± 0.3 
  120 9.8 ± 0.3 10.9 ± 0.3 
 1 5 257 ± 4 322 ± 3 
  30 259 ± 3 313 ± 5 
  60 255 ± 5 267 ± 2 
  120 281 ± 3 279 ± 1 
HP-β-CyD 0.5 5 9.3 ± 0.5 14.3 ± 0.3 
  30 9.5 ± 0.3 13.9 ± 0.3 
  60 9.6 ± 0.2 14.1 ± 0.7 
 1 5 293 ± 1 412 ± 10 
  30 297 ± 6 414 ± 6 
  60 296 ± 6 405 ± 1 
SHS 0.5 5 10.6 ± 0.4 12.5 ± 0.4 
  30 10.7 ± 0.4 10.8 ± 0.3 
  60 10.8 ± 0.5 11.2 ± 0.3 
 1 5 256 ± 1 257 ± 1 
  30 257 ± 2 247 ± 4 
  60 260 ± 3 230 ± 1 
PEG 200 0.5 5 10.1 ± 0.3 14.1 ± 0.3 
  30 9.9 ± 0.8 14.5 ± 0.2 
  60 10.2 ± 0.3 14.2 ± 0.2 
 1 5 304 ± 7 402 ± 3 
  30 304 ± 8 413 ± 4 
  60 307 ± 2 410 ± 4 
TPGS 0.5 5 8.8 ± 0.3 14.6 ± 0.4 
  30 9.1 ± 0.6 14.5 ± 0.3 
  60 8.9 ± 0.2 13.3 ± 0.3 
 1 5 308 ± 5 448 ± 3 
  30 312 ± 7 446 ± 7 
  60 311 ± 3 390 ± 22 
*: Triplicate analyses were conducted on one aliquot for each time point 
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In vitro protein binding of [14C]COM5 using the same plasma pool:  
Total radioactivity concentration determined in plasma and ultrafiltrate 
Excipient Nominal COM5 Actual values 
 
in plasma (ng-eq/mL) 
 (ng/mL) Plasma* Ultrafiltrate 
None 10 8.6 1.3 
(saline)  
 
1.5 
  
 
 
 300 292 35 
  
 
35 
   34 
EtOH 10 10.8 1.3 
   1.2 
    
 300 295 35 
   35 
   34 
CEL/EtOH, 65:35 10 10.4 2.5 
  
 
2.4 
  
 
2.1 
 300 269 65 
  
 
64 
  
 
63 
SHS 10 10.7 3.0 
  
 
2.9 
  
 
3.1 
 300 268 76 
  
 
74 
  
 
73 
*: Mean of duplicate determination of plasma spiked with different COM5 stock solutions 
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Circulation and tissue levels of total radioactivity after iv dosing of [14C]COM5 (1 mg/kg) 
Time Tissue  Individual concentration values (ng-eq/g) 
 (h)  Control group  SHS group 
0.08 Blood* 1109 1450 1365  1694 2005 1859 
 Plasma* 2009 3120 2647  2486 3010 2665 
 Muscle 355 458 387  555 426 448 
 Skin 275 224 245  296 207 219 
 Brain 24 29 28  41 38 41 
0.25 Blood* 712 873 1100  1519 1179 1033 
 Plasma* 1508 1468 1777  2265 1813 1606 
 Muscle 262 341 330  423 445 404 
 Skin 229 242 259  456 441 342 
 Brain 14 16 18  29 27 21 
0.5 Blood* 642 409 792  1096 867 965 
 Plasma* 1194 572 1275  1655 1455 1467 
 Muscle 244 199 241  342 341 315 
 Skin 252 198 256  397 382 374 
 Brain 11 7** 11  22 15 18 
1 Blood* 172 192 219  688 603 464 
 Plasma* 269 304 361  1055 919 727 
 Muscle 59 55 57  203 176 144 
 Skin 164 146 145  299 217 223 
 Brain 3** 3** 3**  12 11 9** 
*: ng-eq/mL, **: value below LOQ 
 
 
Ex vivo protein binding of [14C]COM5 in the control and SHS group: 
Total radioactivity concentration determined in plasma & ultrafiltrate 
 
Time Individual values (pg-eq/mL) 
 
(h) Plasma* Ultrafiltrate 
Control group 0.08 2465 217 221 
 0.25 1587 123 126 
 0.5 1031 69 67 
 1 305 31 31 
SHS group 0.08 2679 378 372 
 0.25 1914 245  
 0.5 1524 230 230 
 1 864 167  
*: Mean of duplicate determination of plasma pooled for each time point 
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